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1 Abbreviations
7-AAD 7-aminoactinomycin D
ABTS 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)
Ab antibody
Ag antigen
AID activation induced deaminase
AIRR adaptive immune receptor repertoire
AtM atypical B cell memory population
AUC area under curve
BCR B cell receptor
BSA bovine serum albumin
CD cluster of differentiation
cDNA complementary DNA
CDR complementarity determining region
CHMI controlled human malaria infection
CM classical B cell memory population
CSP circumsporozoite protein
DNA deoxyribonucleic acid
dNTP deoxynucleotid triphosphate
DTT dithiothreitol
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
EEF exoerythrocytic form
ELISA enzyme-linked immunosorbent assay
FACS fluorescence-activated cell sorting
Fab antigen binding fragment
Fig. Figure
FITC fluorescein isothiocyanate
FSC forward scatter
FWR framework region
HC-04 cells human hepatocyte cells
HEK cells human embryonic kidney cells
HIV Human immunodeficiency virus
HRP horseradish peroxidase
Ig immunoglobulin
LaCHMI Lambare´ne´ controlled human malaria infection
LB lysogeny broth
MN mature naive (B cell)
4
NMR nuclear magnetic resonance
Pb Plasmodium berghei
PB plasmablast
PBMC peripheral blood mono-nuclear cell
PBS phosphate-buffered saline
PCR polymerase chain reaction
Pf Plasmodium falciparum
PFA paraformaldehyde
Pb Plasmodium berghei
Py Plasmodium yoelii
RHP random hexamer primer
RNA ribonucleic acid
RT reverse transcription
SHM somatic hypermutation
SSC side scatter
TuCHMI Tu¨bingen controlled human malaria infection
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3 Zusammenfassung
Plasmodium falciparum ist ein einzelliger Parasit, der im Laufe seines komplexen Lebenszyklus
Anopheles Mu¨cken und Menschen befa¨llt. Sporozoiten sind die Parasitenstadien, die von der Mu¨cke
in den Menschen gelangen. Sie ko¨nnen durch vom menschlichen Immunsystem generierte Antiko¨rper
neutralisiert werden. In dieser Studie wird die humorale Immunantwort, d.h. die Antiko¨rperantwort,
des Menschen auf das wichtigste Oberfla¨chenantigen der Sporozoiten untersucht, das Circumsporo-
zoit Protein (CSP).
Eine ku¨rzlich vero¨ffentliche Studie beschreibt hochaffine CSP-Antiko¨rper, die im Laufe einer Reihe
von kontrollierten humanen Malariainfektionen in europa¨ischen Donoren entstehen, die dem Para-
siten zuvor noch nie ausgesetzt waren. In der vorliegenden Arbeit werden zum einen die molekularen
Eigenschaften ermittelt, die der Bindung dieser Antiko¨rper zugrundeliegen. Außerdem wird unter-
sucht, ob afrikanische Donoren aus einem endemischen Malariagebiet a¨hnliche Antiko¨rper besitzen.
Im Repertoire der europa¨ischen Donoren wurden mehrere Antiko¨rpergruppen identifiziert, die sehr
a¨hnliche Sequenzeigenschaften und Bindungseigenschaften besitzen, obwohl sie aus unterschiedlichen
Spendern stammen. Es wird gezeigt, dass diese Antiko¨rper nur an das Antigen binden ko¨nnen, wenn
pra¨zise Sequenzeigenschaften eingehalten werden. Dies reduziert vermutlich die Anzahl mo¨glicher
B Zell Vorla¨ufer, die zur Entstehung der Antiko¨rper fu¨hren ko¨nnen. Die wichtigste Erkenntnis
dieser Studie ist die Beobachtung, dass Antiko¨rper, die den repetitiven Bereich von CSP binden,
mit sich selbst interagieren und auch Affinita¨tsreifung gegen die Antigenbindungsoberfla¨che des
gegebu¨berliegenden Antiko¨rpers aufweisen. Erstaunlicherweise konnten in den drei untersuchten
afrikanischen Donoren keine Antiko¨rper mit messbarer CSP-Reaktivita¨t identifiziert werden. Die
Arbeit liefert Anhaltspunkte dafu¨r, dass dies zum einen an der Seltenheit der spezifischen B Zell
Vorla¨ufer liegt, aber auch am Bindungsmodus, der durch die repetitive Struktur des Antigens in-
duziert wird.
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4 Abstract
Plasmodium falciparum is a unicellular parasite that throughout its complex lifecycle infects Anophe-
les mosquitos and humans. The parasite stages injected into the human by the mosquito are called
sporozoites and can be neutralized by antibodies generated by the human immune system. The
present study investigates the humoral immune response, i.e. the antibody response, to the major
antigen on the sporozoite surface, circumsporozoite protein (CSP).
A recently published study describes high-affine anti-CSP antibodies, which are generated upon
repeated controlled human malaria infection of European donors, who were never exposed to the
parasite before. The present work on the one hand describes the molecular characteristics that
determine the binding of such antibodies. On the other hand, it investigates whether African donors
from an endemic malaria region exhibited similar antibodies.
In the repertoire of the European donors, several groups of antibodies were identified that share
highly similar amino acid sequences and binding behaviours. It is shown that these antibodies can
only bind to the antigen if very specific sequence characteristics are conserved. This probably restricts
the number of potential B cell precursors that can lead to the generation of such antibodies. The
most important result of this study is the observation that antibodies binding the repetitive region
of CSP directly interact with each other. The antibodies even show signs of anti-idiotope affinity
maturation directed against the antigen binding site of neighbouring antibodies. Surprisingly in none
of the three probed African donors antibodies with measurable anti-CSP reactivity could be found.
The present work suggests that this is due to the low frequency of B cell precursors, but also due
to the specific binding mode that is induced by the repetitive CSP structure.
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5 Introduction
5.1 Circumsporozoite protein as a target of pre-erythrocytic immunity to
Plasmodium falciparum
5.1.1 Plasmodium falciparum life cycle and infection of humans
Plasmodium falciparum (Pf ) is a unicellular protozoan organism that parasitizes its primary mosquito
and secondary human host. As all parasites from the Apicomplexan phylum, Pf undergoes major
phenotypic changes throughout the different stages of its life cycle. The primary host of Pf is the
female Anopheles mosquito, which takes up female and male gametocytes from an infected human
host during a blood meal (Figure 1A). In the mosquito mid-gut the parasites mate, undergo sexual
developmental stages and finally divide and differentiate into sporozoites, which invade the mosquito
salivary gland. During a second blood meal these sporozoites are transmitted into the skin of another
human host (Figure 1B). From the site of injection, the sporozoites migrate to the liver to invade
hepatocytes, the cell type in which they differentiate into exoerythrocytic forms (EEFs). The EEFs
grow, divide and finally differentiate into thousands of first generation merozoites. The latter are
released into the blood stream and undergo multiple rounds of erythrocyte invasion, replication and
cell lysis leading to an exponential growth in parasite numbers (Figure 1C). Some of the merozoites
eventually differentiate into gametocytes, which can infect a mosquito and start another round of
sexual development.
The blood stage replication of Pf in the human host, also called blood stage parasitemia, is the
symptomatic part of the human malaria tropica disease and is accompanied by fever, vomiting,
headaches, and tiredness. It is generally detected by blood smear, staining, and microscopical
detection of blood stages inside the red blood cells. The disease is life threatening if untreated.
The currently available chemotherapeutics against malaria are mostly effective against the blood
stages of the parasite. Chloroquine for example interferes with the haemoglobin metabolism of
merozoites in red blood cells. Resistance against chloroquine has been described in endemic areas.
It is thus sometimes replaced by a combination therapy of lumefantrine and the artemisinin derivate
artemether (Coartem), which is less susceptible to drug resistance.
5.1.2 Pre-erythrocytic immunity against Plasmodium falciparum sporozoites
The successful migration to and infection of hepatocytes by the injected sporozoites is a crucial step
in human malaria and represents a bottleneck in the parasite life cycle. Only approximately 20 Pf
sporozoites are injected into the human skin during a blood meal [11, 87]. It has been postulated
that small numbers of parasites or even single surviving Pf sporozoites can be responsible for
breakthrough of blood stage infection [121].
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Figure 1. Life cycle of Plasmod-
ium falciparum. A female Anopheles
mosquito takes up gametocytes from an
infected human host during a blood meal
(A). Sporozoites develop in the mosquito
and are injected into the human skin from
where they migrate to the liver (B). In-
side the hepatocytes the parasites differ-
entiate to merozoites that are released to
the blood stream and cause symptomatic
blood stage parasitemia (C). Approximate
parasite numbers at the different stages
are indicated as n. Modified from MVI
PATH [77].
A
B
C
n = 10
n = 105
n = 108-1012
Liver
EEFs
hepatocytes
merozoites
Indeed the sporozoite biology is optimized for efficient migration and infection once the parasite is
deposited in the human host. Investigations on the rodent-infecting Plasmodium berghei (Pb) and
Plasmodium yoelii (Py) parasites have shown that after injection into the skin, sporozoites utilize
gliding locomotion to propagate there and eventually reach blood or lymphatic vessels [5, 108].
Parasites ingressing lymphatic vessels are drained to the lymph nodes and mostly degraded [5]. The
parasites reaching the blood stream are carried through the body and access the hepatic tissue via
Kupffer cells [83]. Inside the liver they first traverse several layers of cells [62, 65] before they invade
a hepatocyte and form a parasitophorous vacuole in which they differentiate [129]. The complete
journey between injection and hepatocyte invasion takes only a few hours [32].
Naturally acquired humoral immune responses to the pre-erythrocytic parasite stages are very
rare [46, 104], and seroepidemiological studies failed to prove correlation between pre-erythrocytic
immunity and protection [41, 117]. In endemic areas protection rather correlates with immune
responses to blood stage parasites [31, 40, 74]. It has even been described that semi-immune indi-
viduals carry small parasite numbers in the blood, a phenomenon called asymptomatic parasitemia.
Immunity against blood stage parasites is non-sterile and does not disrupt the parasite spreading,
because semi-immune individuals can serve as parasite reservoirs.
5.1.3 Controlled human malaria infection as a vaccination approach
With the aim of inducing sterile malaria immunity, research has focused on the investigation of con-
trolled infection with live sporozoites as a potential vaccination approach to generate pre-erythrocytic
immunity.
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Controlled malaria infection is a method that has been used already in the early 20th century, first
as a treatment against neurosyphilis, later also as an experimental setup to test the effectiveness
of antimalarial drugs. From the 1960s on investigators started circumventing the symptomatic
blood stage parasitemia by sporozoite attenuation or drug administration and thereby focused the
immune response on the pre-erythrocytic stages. In early studies mosquitos carrying P. berghei
sporozoites were x-ray-irradiated and then used to infect mice. Development of protective immunity
was observed in these experiments [72]. In subsequent studies with humans, mosquitos carrying
Pf sporozoites were irradiated [19, 42] and then used to infect study participants. Later also non-
attenuated living sporozoites were used to infect humans by intra-dermal administration. The blood
stage development of Pf was impeded by chloroquine chemoprophylaxis [9]. It was confirmed that
the protection after controlled malaria infection is mainly mediated by pre-erythrocytic immunity [13].
Antibodies and memory B cells against pre-erythrocytic targets are induced in mice [43, 81, 130]
and humans [10, 70]. It is nevertheless difficult to correlate them with protection against parasite
infection.
Very recent studies utilizing intravenously injected live Pf sporozoites as immunogen in a vaccination
approach (Sanaria PfSPZ-CVac) have demonstrated complete protection after a three repeated
controlled infections [64]. During the course of the vaccination patients are under chloroquine
chemoprophylaxis and the parasite thus cannot initiate the symptomatic infection of red blood cells.
In addition the number of injected sporozoites is in general by orders of magnitude higher than the
one injected during a mosquito blood meal, providing the immune system with large amounts of
antigen. The protein based pre-erythrocytic vaccine RTS,S/AS01 (Mosquirix) is less effective and
only reaches 25-50% vaccination efficacy in infants and young children [89, 90].
5.1.4 Circumsporozoite protein is one of the major pre-erythrocytic antigens
Circumsporozoite protein (CSP) is the major antigen on the mature sporozoite surface. The protein
was first described and isolated in Pb as Pb44 and proven to be important for parasite infectivity [4,
81, 128]. Indeed, CSP is important in the context of ingression of the sporozoites into the liver
tissue. A conserved region C-terminal part of the protein binds to heparan sulfate proteoglycans
associated with the surface membrane of hepatocytes [33, 97]. CSP is the most abundant molecule
on the parasite surface: the number of molecules per parasite was estimated to around 106 [82].
The overall structure of CSP is conserved throughout different Plasmodium species: the protein is
anchored to the cell surface by a GPI-anchor and composed of three major domains, an N-terminal,
a C-terminal domain and a central repeat domain (Figure 2A). However, different Plasmodium
species have different CSP protein sequences, with major differences in the sequence of the central
repeating amino acids. In Pf the repeat region of CSP consists of around 40 repeat units of a
NANP amino acid sequence followed in proximity to the N-terminus by several alternated repeat
sequences including NVDP cadences. In field isolates of Pf strains from an endemic region, different
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N-Term C-Term GPI 
(NANPNVDP)4 (NANP)40 
Vaccine RTS,S A 
B C 
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X-Ray 
Figure 2. Structure of Pf CSP. A: Pf CSP is composed of an N-terminal, a C-terminal domain and
a central repeat region composed mainly of NANP repeats but also few NVDP motifs in proximity
to the N-terminus. It is anchored in the membrane with a GPI anchor. The stretch used in the
vaccine RTS,S AS01 is indicated. B: NMR and X-ray studies have shown that single NANP repeats
adopt a loop structure [14, 36, 79]. C: The NANP-repeat sequence can adopt type-I, type-II folding
sequences due to rotamers of proline [36].
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lengths of the repeat region and repeat numbers have been reported [15]. The repeat seems to
evolve by concerted evolution, which means that repeat arrays can expand or contract by internal
duplications or deletions [15]. Although a fully resolved structure of the CSP molecule does not
exist, several studies describe structural characteristics of the smaller Pf CSP subregions like the
C-terminus or single repeat-motifs [14, 36]. Summarizing these findings and using computational
structure modelling, Pf CSP has been described to exhibit a flexible, rod-like structure with a high
proportion of disordered protein stretches [79]. The Pf CSP component of the vaccine RTS,S is
composed by the C-terminus and a stretch of NANP repeats.
The central repeat region of Pf CSP is very particular in its sequence and structure because it is
composed by a long stretch of so-called tandem repeats, a characteristic which is seldom observed in
proteins. By the use of NMR [14] or crystallography [36], it has been shown that the NANP-repeat
adopts a loop structure [79] (Figure 2B). This secondary structure is facilitated by the prolines that
can adopt both cis- and trans-conformations allowing the formation of type-I and type-II beta turns
that are stabilized by hydrogen bonds within the repeat [36] (Figure 2C).
5.2 Humoral immunity
5.2.1 B cells generate specific antibodies in response to a foreign antigen
The adaptive immune system has evolved to efficiently and sustainably protect complex organisms
from invading pathogens. The humoral immune system is the part of the adaptive immune system
that generates antibodies as effector molecules. B cells are the cellular agents of humoral immu-
nity responsible for antibody production. They develop in the bone marrow where they undergo
multiple steps of differentiation and pass immune checkpoints that eliminate cells with potential
auto-reactivity. After development every mature naive B cell carries a unique B cell receptor (BCR)
on its surface, which is encoded by immunoglobulin loci that partially recombine during development.
Figure 3 depicts the evolution of B cells during an infection. Mature naive B cells that are able to
recognize the foreign antigen with their BCR, are activated via a BCR-induced signalling cascade,
proliferate, and migrate to secondary lymphoid organs such as lymphnodes or spleen to finally enter
germinal center reactions (Figure 3A and B). In these germinal centers the foreign antigens are
presented to B cells, which can internalize them if their BCR has a sufficient affinity to the antigen.
The antigen is processed by the B cell and presented to follicular helper T cells that provide additional
activation signals to those B cells that successfully presented the antigen (Figure 3D). Activated
B cells proliferate and undergo clonal expansion. In addition, somatic hypermutation is used to
introduce small alterations into the DNA sequence of the immunoglobulin gene and eventually
change the affinity of the BCR to the antigen, a process called BCR diversification (Figure 3C).
The enzyme primarily responsible for somatic hypermutation is called activation induced deaminase
(AID), and raises mutation rates up to 10−3 mutations per base pair and division [12]. Antigen
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A 
B 
C 
D 
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F 
Figure 3. B cell activation and differentiation during the course of an immune reaction.
Mature naive B cells are activated by binding of antigen to their B cell receptor and help of cognate
CD4 T cells (A) and start to proliferate inside B cell zones of secondary lymphoid organs (B).
Some of the activated B cells enter germinal centres where they undergo clonal expansion and BCR
diversification by somatic hypermutation (C). In affinity selection single B cells compete for binding
of antigen presented by follicular dendritic cells (FDC) and T cell help (D). When exiting germinal
centers, affinity matured B cells can either differentiate into memory B cells or long-lived plasma cells
(E). It has also been reported that some B cells differentiate into non-germinal center dependent
memory B cells and plasma cells directly after first activation (F). Adapted from [55]
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specific clones inside germinal centres thus compete for antigen binding and T cell help over several
rounds of division and affinity maturation [109].
A B cell exiting the germinal center reaction can differentiate into either memory B cell or plasmablast
(Figure 3E). Memory B cells are generally long-lived cells that keep their BCR surface expression,
can be reactivated during a second infection and ensure a faster and more efficient secondary
response upon reinfection with the same pathogen. Plasmablasts start to secrete antibodies instead
of expressing the immunoglobulin genes as BCRs, a mechanism mediated by alternative splicing of the
Ig transcript. They migrate to the bone marrow where they can differentiate into antibody-secreting
plasma cells that provide antibodies to combat the current infection. Plasma cells can also maintain
antibody titers to prevent secondary infections. The differentiation into either plasmablast or memory
B cell is affinity and time dependent, with memory B cells produced in early germinal centers and
higher affine plasmablasts in later stages [96, 119]. Plasmablasts are found in the peripheral blood
approximately 7-10 days after an infection [17]. An atypical population of memory cells, characterized
by their lack of the typical memory marker surface expression, has been described in chronic infections
like HIV or malaria. Their exact origin and function remains unclear and studies draw diverging
conclusions regarding their activation status, functionality and antibody secretion [63, 66, 80, 100].
In addition to the germinal center dependent generation of memory and plasmablasts, B cells have
also been described to be able to differentiate into memory and plasmablasts directly after first
antigen encounter without entering germinal centres [55] (Figure 3F).
5.2.2 Immunoglobulin structure diversity generation
Immunoglobulins, or antibodies, are Y-shaped molecules composed of two heavy (H) and two light
(L) chains held together by disulphide bonds (Figure 4A). Each one of these chains is composed
of a variable (V) and a constant domain (C). Different functions of the antibody molecule can
be attributed to the different structural domains: the constant domain is responsible for antibody
effector functions such as complement activation or opsonization, whereas the variable domain is
responsible for antigen specificity. The two heavy constant domains are connected via disulphide
bonds at the level of the antibody’s hinge region. The hinge region is responsible for the flexibility
of the two antibody arms. Different effector functions and constant domain structures or flexibilities
are covered by the different isotypes. In humans these isotypes are IgD, IgM, IgG1, IgG2, IgG3, IgG4,
IgE, IgA1 and IgA2. During the course of an immune response, the gene encoding the constant
domain of a BCR can be replaced by a recombination process (class switch recombination) that also
involves the above mentioned germinal center dependent enzyme AID.
The tips of the variable heavy and light chain domains compose the paratope of an antibody, i.e.
the site where the antigen usually is bound. Subregions of the variable region which build the
antigen-binding surface are called complementarity determining regions (CDR), whereas the protein
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Figure 4. Structure and diversity of antibody molecules. A: Structure of an antibody molecule
with heavy (H) and light (L) chains. Each chain is composed of a variable (red) and a constant
(blue) region. The variable region forms the antigen binding site. The heavy chains are linked via
disulphide in the hinge region. B: Protein structure of a variable heavy chain shown as cartoon. The
complementarity determining regions (HCDR) define the antigen binding site. Framework regions
(FWR) are shown in light pink. C: V(D)J recombination of heavy and light chain loci. V, D and
J segments are recombined to encode the variable region. CDR1 and CDR2 are encoded by the
IGHV gene, whereas CDR3 is located at the V(D)J recombination site and is thus the most variable.
In the mature mRNA the exons encoding the constant region are assembled by splicing. Modified
from [67].
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Table 2. Number of Ig genes according to the IMGT database [56]
Locus Chromosomal localization V D J C
IGH 14q32.33 123-129 27 9 11
IGK 2p11.2 76 0 5 1
IGL 22q11.2 73-74 0 7-11 7-11
stretches distal from the paratope are called framework regions (FWR) (Figure 4B). The location
of these regions is usually defined based on analysis of surfaces of known antibody structures, as for
example in the Kabat scheme [123]. During B cell development the genomic regions encoding the
variable domain of the BCR are recombined (Figure 4C). For the heavy chain a VDJ recombination
takes place, which means that one IGHV, one IGHD and one IGHJ segment are chosen from a
pool of germline segments and joined by a process that involves deletion and addition of so called
palindromic (P) and non-template (N) nucleotides. The light chain can be either encoded by the
kappa or the lambda locus where a VJ recombination takes place. Table 2 summarizes the numbers
of heavy, kappa and lambda germline genes present in humans.
The aleatory recombination of gene segments, the addition and deletion of nucleotides in the junction
as well as the combination of heavy and light chain are responsible for the diversity of the human
naive B cell repertoire. The actual diversity of the complete human naive heavy chain repertoire
has been estimated to 1018 possible sequences, i.e. much larger than the approximately 1012 B cells
present in an individual [28].
In addition to the intrinsic generation probabilities of single sequences, the B cell repertoire is also
influenced by the genetic background of every individual. In studies describing the heterogeneity of
the loci encoding human immunoglobulin variable chains, it has indeed been found that the variable
germline genes are not only subject to single nucleotide polymorphisms or allelic variants, but that
a great proportion of the diversity is also due to structural polymorphisms such as deletions or
duplications [114].
5.2.3 Dynamics of antibody antigen recognition
During antigen binding of BCRs or antibodies, the immunoglobulin paratope formed by three heavy
and three light CDR regions interacts with the epitope of an antigen. The molecular forces determin-
ing the affinity of the interaction are electrostatic forces, hydrogen bonds, hydrophobic interactions
and van-der-Waals forces. Different types of shape complementarity have been described as for
example long HCDR3 loops intruding binding pockets in large antigen molecules [91], or binding
grooves for antigen peptides [85]. It has also been demonstrated that specific residues like tyrosine
are more often involved in antigen binding than other amino acids [84, 86].
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The affinity of an antibody (Ab) interaction with an antigen (Ag) interaction is defined as the
equilibrium constant of the reaction
Ab+ Ag  AbAg.
The affinity constant of the reaction at steady state is then
KD =
Koff
Kon
= [Ag][Ab][AbAg] ,
where Kon and Koff are the association and dissociation rates of the reaction which can also be
determined individually by affinity measurement in a surface plasmon resonance setup for example.
Since antibody molecules have at least two binding sites (more for multimeric forms of IgM e.g.),
avidity, which represents the overall binding rate of an antibody complex to an antigen, plays a
major role. On the B cell surface, binding of BCRs to antigen and the thereby induced cross-linking
induces B cell activation. It has been reported that if the nature of the antigen allows efficient cross-
linking of B cell receptors, the B cell can get activated even without T cell help. These antigens are
called T cell independent antigens and are particularly bacterial polysaccharides and other repetitive
antigens.
5.2.4 Public antibody repertoires
Despite the enormous heterogeneity of recombination sequences, several studies have described the
development of antibodies with convergent amino acid sequence features in multiple individuals after
the exposure to common immune stimuli [35, 48, 76, 98, 105]. Even when sequencing complete
antigen-experienced memory repertoires of individuals, public antibodies were identified, although
with a extremely low frequency of 1 in 35,000 antibodies [24]. These common or public antibodies are
of biological interest, because antibodies with similar sequence also are likely to have similar functions
and binding behaviours. The successful identification and characterization of public antibodies could
for example help to diagnose certain diseases or also to determine the effectiveness of a specific
vaccination.
However, the difficulty in this approach lies in the successful clustering method that not only iden-
tifies antibodies with similar sequences but also only antibodies where similar sequences coincide
with similar functionality. Antibodies are quite similar already due to the process that generates
them at first. Various approaches have been used to identify public antibodies: complete HCDR3
identity, partial HCDR3 identity, similarity of only H chains or paired H and K chains. Datasets used
in these analyses often stem from very different sources, including bulk repertoire sequencing that
does neither allow an assessment of the complete antibody sequence nor the mapping of immunol-
gobulin sequences to single cells. The explanatory power of such investigations, however, is strongly
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influenced by the quality and resolution of the utilized datasets. Very little work was done so far on
testing the function of the identified public antibodies.
5.3 Open questions
5.3.1 Public antibody repertoires against the pre-erythrocytic parasite stages
The present study seeks to characterize the public antibody repertoire generated in humans after
natural exposure and controlled human malaria infection. Previous research on antibodies sequenced
and cloned from the controlled human malaria infection of Pf naive European donors which demon-
strated pre-erythrocytic immunity [64] identified a considerable number of protective anti-Pf CSP
antibodies [69]. The majority of these antibodies was of the IgM isotype and specific to the central
NANP-repeat region of the Pf CSP protein. This study also identified common sequence features
of the anti-Pf CSP antibodies, as for example usage of IGHV3-33 and KCDR3 regions of 8 amino
acids. However it remains unclear whether these sequence features also represent a common binding
mechanism of antibodies to Pf CSP or whether they are enriched for reasons that are independent
of antigen binding.
Up to date there are no high-throughput datasets on naturally acquired antibodies against pre-
erythrocytic antigens, mainly because these antibodies are very rare and thus difficult to isolate.
Previous studies on naturally acquired antibodies only analysed small numbers of these and did
not identify sequence features that characterized the Pf CSP specific repertoire [73, 104]. It thus
remains unclear to what extent naturally acquired antibodies are similar to the ones generated during
controlled human malaria infection.
5.3.2 Anti-Pf CSP antibodies
Antibodies binding Pf CSP can be in general directed against the C-terminus, the N-terminus, or the
central repeat region. However, this study focusses on antibodies with affinity to the NANP-repeat,
because they are the ones most often observed. Screening of anti-Pf CSP antibodies against a library
of synthetic repeat peptides has shown that these antibodies can be grouped according to the repeat
cadences that they preferentially bind. The succession of N and P amino acids seems to be the most
important cadence [122]. Indeed, recently resolved crystal structures have shown that antibodies
can bind different small structural epitopes within the repetitive NANP-sequence [75, 104].
However, it is still not clearly described what sequence features mediate the binding of antibodies
to the different repeat epitopes. Interestingly, for the antibodies from the controlled human malaria
infection it was found that high affinities to the repeat can be reached even with very low numbers of
somatic hypermutations [69]. This indicates that high quality germline encoded antibodies against
Pf sporozoites exist. Similarly, two naturally acquired repeat binding antibodies with higher number
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of somatic hypermutations have been shown to utilize mainly germline encoded residues for antigen
binding [104]. Especially for the design of new vaccination strategies, it is important to understand
how to efficiently target the germline precursors of high-quality B cell responses.
Another phenomenon that is still not well described is the impact of the Pf CSP repeat structure
on the affinity maturation of the antibodies. In the antibodies isolated during the CHMI trial it was
observed that affinity maturation plays a minor role for acquisition of high-affine antibodies and that
clonal selection is more relevant. A mathematical model identified the complexity of the Pf CSP
molecule as a reason for this phenomenon [69]. Moreover, biophysical investigations on murine and
human antibodies directed against Pf CSP have shown that the repetitive structure of the protein
favours multimeric binding of antibodies [30, 75].
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6 Objectives
The overall goal of this thesis was to describe the molecular features of the public human antibody
repertoire directed against the major sporozoite surface antigen Pf CSP. More specifically, the study
had the following aims:
• Aim 1: Compare the Pf CSP-specific B cell repertoires in malaria naive and malaria experienced
donors after controlled human malaria infection.
• Aim 2: Test to what extent the Pf CSP-specific public B cell repertoire can be defined using
sequence data.
• Aim 3: Molecularly characterize several antibodies from this public repertoire and define the
germline encoded sequence characteristics that determine their binding.
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7 Material and Methods
7.1 Controlled human malaria infections and sample preparation
7.1.1 Tu¨bingen controlled human malaria infection (TuCHMI)
Parts of the repertoire data and antibodies analysed in this thesis were generated earlier using
samples from the TuCHMI controlled human malaria infection conducted by Benjamin Mordmu¨ller
and colleagues in Tu¨bingen, Germany [64, 69]. In this study Plasmodium falciparum naive donors
under chloroquine chemoprophylaxis treatment were infected three times with 51,200 live sporozoites
with 28-day intervals. After another ten weeks the donors were challenged. The relevant time points
for the present work are blood samples collected at day 7 after parasite injection. If not specified
otherwise, the methods utilized for acquisition of the Tu¨bingen data were the same as the ones
described in the following sections.
The study was approved by the ethics committee of the medical faculty and the university clinics of
the University of Tu¨bingen and strictly adhered to Good Clinical Practice and the principles of the
Declaration of Helsinki. The clinical trial from which the samples were obtained was registered un-
der https://clinicaltrials.gov/ct2/show/NCT02115516 and number 2013-003900-38 in the EudraCT
database and carried out under FDA IND 15862 and with approval of the Paul-Ehrlich-Institute [64].
7.1.2 Lambare´ne´ controlled human malaria infection (LaCHMI)
The LaCHMI controlled human malaria infection was conducted in the Centre de Recherches
Me´dicales de Lambare´ne´ (CERMEL) at the Albert Schweitzer Hospital in Lambare´ne´, Gabon [57].
The study was approved by the Gabonese national ethics committee (Comite´ National d’Ethique
de la Recherche), and conducted under a US FDA Investigational New Drug application (IND).
The study followed the principles of the Declaration of Helsinki in its 6th revision as well as the
”International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use – Good Clinical Practice (ICH-GCP)” guidelines. The study is registered with ClinicalTrials.gov,
number NCT02237586 [57].
20 presumably Pf experienced Gabonese and 5 Pf naive donors aged between 18 and 29 years
were pretreated with antibiotics 5 days prior to the study begin to eliminate all possibly remaining
parasites from previous infections. At day 1, the donors were injected with 3,200 live Pf sporozoites
intravenously. Starting on day 5, blood smear parasitemia screens were performed every day. 2 mL
of peripheral blood was collected every second day by venous puncture. 20 mL of blood for B cell
receptor sequencing were collected on day 7, 13, 19 or 21 and 28.
Donors were determined positive when at least 2 parasites were found on a slide by at least two
independent slide readers (day of parasitemia, DoP). European donors were treated with anti-Pf
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chemotherapy (Coartem) immediately after first positive thick blood smear, whereas Gabonese
donors were treated when developing symptoms or reaching a threshold parasitemia of 1000 parasites
per µL (day of Drug, DoD). Donors, who did not develop parasitemia, were treated on day 28, to
eliminate all possibly remaining parasites.
7.1.3 Isolation of PBMCs
Peripheral blood was collected in Heparin tubes and centrifuged at 800g for 20 min. The serum
was collected and the remaining blood components diluted 1:1 with RPMI medium. Peripheral
blood mononuclear cells (PBMCs) were isolated using Percoll gradient density centrifugation at
800g for 20 min. The PBMC layer was isolated using a Pasteur pipette and washed twice in RPMI.
5x106 PBMCs per mL and per vial were resuspended in 10% DMSO in FCS and frozen using a
CoolCell cell freezing device and a -80 °C freezer. After 24 h the tubes were transferred to liquid
nitrogen. Frozen PBMC samples where shipped to Berlin, Germany using a dry shipper container
cooled with liquid nitrogen. Serum samples were shipped on conventional ice at 4 °C and refrozen
at -80 °C when arriving in Berlin.
7.1.4 IGHV genotyping
Genomic DNA was extracted from whole blood (TuCHMI donors), or from sorted mature naive
(MN) B cells (LaCHMI donors). IGHV3 genes were amplified using a set of barcoded 5’ primers
and a mix of J-segment specific 3’ primers (appendix, section 13.3.4). The PCR mix composition
is shown in table 3, the PCR program was the same as for the 1st PCR amplification described in
table 8. The amplicons were pooled and prepared for sequencing using a PCR-free library-prep kit
(Illumina). Sequencing was performed on a Illumina MiSeq instrument using a 300-300bp paired
end sequencing protocol. The DKFZ sequencing core facility offered the sequencing service and
a basic sequencing quality control. Sequencing reads were then assembled using PandaSeq ([60],
parameters: t = 0.8, minimum length = 320, maximum length = 550) and assigned to the donors
by barcode identification. The resulting sequences were annotated using IgBLAST [126] and an
in-house human genomic immunoglobulin database and pre-filtered on ”IGHV3-3*”-like gene usage
applying regular expression filtering. Every sequence was classified into the gene groups IGHV3-33,
IGHV3-30 or IGHV3-3-30 depicted in Figure 17A using exact sequence matching of HCDR2 on
nucleotide level.
7.1.5 Flow cytometric quantification of B cell populations
During the LaCHMI study, every second day 1-2 million isolated PBMCs were stained for flow
cytometric analysis. PBMCs were centrifuged at 800g for 3 minutes and the pellets resuspended in
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Table 3. PCR reaction mix for IGHV genotyping
PCR component amount [µL]
PCR grade water 38.95
10x PCR Buffer 5
dNTPs [25 mM each] 0.4
Fw Primer [50 µM] 0.2
Rv Primer [50 µM] 0.2
HotStar Taq polymerase 0.25
Genomic DNA (2 ng/µL) 5
a primary staining mix composed of the following antibodies in 2% FCS in PBS (FACS buffer): CD19-
PE-Cy7 (1:20), CD20-APC-H7 (1:10), CD21-PE (1:20), CD38-APC (1:20), CD27-FITC (1:5). After
30 minutes of incubation, cells were washed with FACS buffer and stained with the live/dead marker
7-AAD (1:400 in FACS buffer). After 10 minutes of incubation, the cells were again washed,
resuspended in FACS Buffer and analysed on a Guava easy Cyte Cytometer. The data was analysed
using FlowJo v10.0.
7.2 Antibody repertoire sequencing
7.2.1 Fluorescence activated cell analysis and single-cell sorting
PMBCs were thawed and washed in RPMI medium and pelleted at 500g for 5 min before the staining
procedure. All sample preparation, staining steps and sorting was performed at 4 °C. NF54 Pf CSP
was a kind gift of Dr. Kim Lee Sim (Sanaria Inc., Rockville, Maryland, USA) and was chemically
coupled to Alexa647 according to labelling kit the manufacturer’s protocol (Thermo Fisher Scientific
Inc.). PBMC pelets were first resuspended and stained with the Alexa647-labelled Pf CSP in 2%
FCS in PBS (FACS buffer) for 30 min.
Cells were washed with 1 mL FACS buffer, pelleted as described above and stained for 45 minutes
using with the following antibodies in FACS buffer: CD27-PE (1:10), CD38-FITC (1:10), CD21-PE-
Cy7 (1:20), IgG-APC-H7 (1:20), IgD-BV510 (1:20), CD138-BV421 (1:20), CD19-BV786 (1:10),
CD20-BV711 (1:20). Cells were again washed and stained for 10 min with 7-aminoactinomycin D
(7AAD, 1:400) as a live-dead marker. Finally cells were washed, pelleted and resuspended in FACS
buffer and analysed or sorted on a BD FACS ARIA II cell sorter with a cooled plate stage.
Cell doublets were excluded based on FSC-H/W and SSC-H/W. Single cells were sorted into 384-
well plates containing 2 µL of lysis/RHP buffer. The plates were immediately sealed, frozen on dry
ice and stored at -80 °C. The lysis/RHP buffer consisted of the following components as shown in
table 4: the reducing agent DTT for the disintegration of secondary RNA structures, NP-40 for cell
lysis, RHP to initiate the transcription process and the RNAse inhibitor RNAsin.
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Table 4. Sort reaction mixture
Sort mix component stock concentration amount [µL]
water - 1.4813
PBS 10x 0.0500
DTT 100 mM 0.1000
NP-40 10% 0.1375
RHP 300 ng/µL 0.1375
RNAsin 40 U/µL 0.0938
total 2.0000
Table 5. Reverse transcription reaction mixture
RT mix component stock concentration amount [µL]
water - 0.6375
RT-buffer 5x 0.8000
DTT 100 mM 0.3000
dNTPs 25 mM each 0.1375
RNAsin 40 U/µL 0.0563
SuperScript III/IV 200 U/µL 0.0688
total 2.0000
7.2.2 Ig gene amplification from single B cells
Sorted 384-well plates were shortly thawed on ice and then incubated at 68 °C for 60 sec to break
secondary RNA structures. 2 µL of the RT mix for cDNA synthesis were added. The RT mix
was composed of the following reagents as shown in table 5: RT enzyme buffer, DTT, dNTPs,
RNAsin and the reverse transcriptase SuperScript III. The reaction was carried out on a Eppendorf
Matercycler with the following steps: denaturation of RNA (5 min, 42 °C), annealing of hexamers
(10 min, 25 °C), reverse transcription (60 min, 50 °C), reaction stop (5 min, 94 °C).
The cDNA synthesis product was used as template for a first Ig gene specific PCR. The product of
this reaction was then used for a second gene specific PCR with barcoded primer sets. The PCR
composition and cycler protocol is described in Tables 6 - 8. The gene specific parts of both primer
sets are shown in the appendix, section 13.3.1. All pipetting steps for the RT-PCR were carried out
on a Tecan Evo200 automation platform as described in [16].
7.2.3 Sequencing of Ig amplicons
In order to enable high throughput sequencing on an Illumina platform, sequencing adaptors have
to be ligated to the amplicons. Illumina TruSeq PCR-Free LT Kit was used for adaptor ligation
according to the manufacturer’s protocol. The amount of amplicons with adaptors ligated to both
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Table 6. First PCR reaction mixture with Ig specific primers
1st PCR reagent stock concentration amount [µL]
water - 7.7900
buffer 10x 1.0000
5’ primer mix 50 µM 0.0325
3’ primer mix 50 µM 0.0325
dNTPs 25 mM each 0.1000
HotStar Taq polymerase 5 U/µL 0.0450
template 1.0000
total 10.0000
Table 7. Second PCR reaction mixture with Ig specific primers
2nd PCR reagent stock concentration amount [µL]
water - 7.7900
buffer 10x 1.0000
5’ primer mix 50 µM 0.0325
3’ primer mix 50 µM 0.0325
dNTPs 25 mM each 0.1000
HotStar Taq polymerase 5 U/µL 0.0450
template 1.0000
total 10.0000
Table 8. PCR programs for Ig gene amplification
Step Duration Heavy Kappa Lambda Cycles
Initial denaturation 10 min 95 °C 95 °C 95 °C 1
Denaturation 30 sec 95 °C 95 °C 95 °C
Annealing 30 sec 58 °C 58 °C 60 °C 50
Elongation 55 sec (1st PCR), 45 sec (2nd PCR) 72 °C 72 °C 72 °C
Final elongation 10 min 72 °C 72 °C 72 °C 1
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ends was measured using the KAPA Quant qPCR kit on a Roche 480 light cycler instrument.
Amplicons were then pooled in appropriate ratios and sequenced on a Illumina MiSeq platform using
a 300-300 bp paired end sequencing protocol in the DKFZ Sequencing Core Facility. 30-40 % of
PhiX DNA was added to the sample before sequencing to reduce biases due to non-heterogeneous
base distribution.
7.3 Computational sequence analysis
7.3.1 Sequence annotation using sciReptor
Paired end reads from the Illumina run were assembled using PandaSeq [60]. The parameters set
during the pandaseq run were: t = 0.8, minimum length = 320, maximum length = 550. Assem-
bled reads were analysed using the sciReptor pipeline for analysis of single-cell sequencing data ([47],
github.com/b-cell-immunology/sciReptor). Briefly, single reads were attributed to their respective
well barcodes identified by RazerS analysis [118]. V and J segments as well as somatic hypermuta-
tions, constant segment usage and CDR/FWR regions were annotated. The flow cytometric index
data and meta-information was associated to every single cell using the R flowCore package [29].
The data was stored in a MySQL database framework using a MariaDB server. Subsequent sequence
analysis and plotting was done using python 2.7, especially the matplotlib [45], numpy [106].
7.3.2 Sequence similarity and repertoire clustering
In order to characterize repertoire similarity, pairwise sequence distance between all observed se-
quences was calculated independently for heavy, kappa and lambda repertoire. For this purpose
sequences were aligned using the Biopython alignment algorithm pairwise2.align.globalxx [20]. As
distance measure the hamming distance was calculated with gaps and mismatches counting 1. The
distance was normalized to the length of the alignment. For clustering of the resulting pairwise
distance matrices python networkx package was used [38]. Plotting of circular cluster diagrams was
done using circos [54].
7.3.3 Background model for somatic hypermutation
The background model for somatic hypermutation was taken from the shazam package with standard
settings [37, 125]. Sets of computationally mutated IGHV3-33, IGHV3-23 and IGKV1-5 sequences
were generated in fashion to have similar mutation levels as the observed datasets. Computed and
observed sequences were translated using Biopython [20] and the amino acid frequencies compared
at defined positions.
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7.4 Recombinant antibody expression
7.4.1 Cloning of immunoglobulin genes
After sequence analysis, specific antibodies were selected for recombinant expression, in order to
test their antigen binding.
Preparation of heat competent E. coli
E. coli DH10B were grown in 500 mL of lysogeny broth (LB) medium to an OD600 of 0.5. After an
incubation of 30 min on ice cells were centrifuged for 10 min at 3200g and 4 °C and the pellet was
resuspended in 70 mL of ice-cold 0.1 M CaCl2. The bacterial cells were centrifuged, resuspended
in 50 mL 0.1 M CaCl2 solution supplemented with 15% glycerol and snap-frozen in liquid nitrogen.
50 µL aliquots of the competent bacteria were stored at -80 °C. The transformation efficiency
(competency) was determined by test transformation vector in amounts ranging between 1 and
10−5 ng of DNA.
Expression vectors
Three vectors were used for expression of antibody heavy and light chains: AbVec2.0-IGHG1,
AbVec1.1-IGKC and AbVec1.1-IGLC2-XhoI [103]. DNA preparation of these vectors was performed
as described in ”Transformation into heat competent bacteria” and ”Vector preparation”. Maps of
the three expression vectors are depicted in the Appendix, Section 13.4.
Specific amplification of immunoglobulin genes
In order to clone the heavy and light chain amplicons into the respective expression vector, another
PCR was carried out using primers which introduce restriction sites at the 5’ and 3’ end of the heavy
and light chain amplicons. Primer sequences can be found in the appendix, section 13.3.2. SalI,
BsiWI and XhoI were used as 3’ restriction sites for heavy, kappa and lambda chains respectively.
The 5’ restriction site was an AgeI site for all three chains. In the specific PCR, 3.5 µL of the 1st
PCR mixed with 7.5 µL of water were used as template. The reaction set-up is shown in table
9. The PCR was run with the thermocycler program for the secondary PCR of the heavy chain
(Table 8). Amplification was verified by gel electrophoresis. PCR products were purified using the
NucleoSpin 96 PCR clean-up kit (Macherey-Nagel GmbH).
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Table 9. PCR reaction for amplification of Ig genes for cloning
Specific PCR reagent stock concentration amount [µL]
water - 21.42
buffer 10x 4.00
5’ primer mix 3.3 µM 2.00
3’ primer mix 3.3 µM 2.00
dNTPs 25 mM each 0.40
HotStar Taq polymerase 5 U/µL 0.18
total 26.0000
Restriction endonuclease digestion of vector and inserts
The amplicons of the heavy and lambda chain of the Ig genes obtained in the specific PCR and
the purified Igγ1 and λ vectors were double-digested with the respective enzymes (heavy: AgeI-
HF/SalI-HF, lambda: AgeI-HF/XhoI, New England Biolabs) for 2 h at 37 °C. As different incubation
temperatures for the enzymes AgeI and BsiWI were required, a 2-step digest was carried out for
the amplicons of the kappa chain and the Igκ vector, first digesting with AgeI-HF for 2 h at 37 °C
and then for 2 h at 55 °C after adding BsiWI. All digests were carried out according to the enzyme
manufacturer’s protocol. The digested PCR products were purified using the NucleoSpin 96 PCR
Clean-Up kit from Macherey-Nagel GmbH. The digested vectors were separated by gel electrophoresis
using a 1% agarose gel. The linearized vectors were excised and the DNA purified according to the
manufacturer’s protocol using the NucleoSpin Gel and PCR Clean-up kit (Macherery-Nagel GmbH).
Ligation
The digested PCR products of the heavy, kappa and lambda chains were ligated into the respective
expression vectors using T4 DNA Ligase. Ligation was carried out at 16 °C overnight.
Transformation into heat competent bacteria
For transformation 10 µL of heat competent bacteria were transferred to a microcentrifuge tube
on ice. 3 µL of ligation product (or 0.4 µL of vector DNA in the case of retransformation) were
added and the mixture incubated on ice for 30 minutes. A heat shock at 42 °C was performed for
45 seconds. The bacteria were cooled down again on ice for 2 minutes before adding 100 µL of
LB-medium. The cultures were incubated for 40 minutes at 37 °C and 650 rpm and then plated on
LB-agar plates containing 100 µg/mL ampicillin.
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Table 10. PCR reaction mixture for insert check
Insert check PCR reagent stock concentration amount [µL]
water - 20.975
buffer 10x 2.5
5’ primer mix 50 µM 0.2
3’ primer mix 50 µM 0.2
dNTPs 25 mM each 0.125
HotStar Taq polymerase - 1.00
total 25.0000
Screening of bacterial colonies by PCR
Transformed bacterial colonies were screened for the correct insertion of the heavy, kappa or lambda
variable insert. For this purpose, a colony PCR was performed where bacterial colonies were directly
added to the PCR master mix described in Table 10.
The 5’ primer Absense, which binds to a vector sequence upstream of the inserted PCR product, was
used for all three vectors. Primers specific for the individual constant regions of human Igγ1, Igκ
and Igλ were used as 3’ primers: hIGHG-084-Rv for Igγ1, hIGKC-172-Rv for Igκ and hIGLC-057-Rv
for Igλ. PCR products were analyzed on a 2% agarose gel for their expected sizes of 650 bp for
Igγ1, 700 bp for Igκ1 and 590 bp for Igλ. To exclude PCR-induced point mutations or frame-shift
occurring through the insertion of the PCR products into the vectors, the PCR products were Sanger
sequenced with Absense primer. The sequences were compared to the sequences initially obtained
during repertoire sequencing. A list of the primers can be found in the appendix, section 13.3.3.
Vector DNA preparation
For miniprep, 6 mL of terrific broth (TB) medium with 75 µg/mL ampicillin were inoculated with a
bacterial colony. For maxiprep, 500 mL of LB Medium with 75 µg/mL ampicillin were inoculated. In
both cases DNA preparation was performed according to the manufacturer protocol using plasmid
purification kits (Macherery-Nagel GmbH). DNA concentration and purity were assessed using a
NanoQuant plate in a Tecan M1000 Pro plate reader.
7.4.2 Site directed mutagenesis
Site directed mutagenesis on the antibody encoding plasmids was performed using the Q5 site
directed mutagenesis kit (Quiagen). The primers are summarized in the Appendix, Section 13.3.5.
The successful introduction of mutations was verified by sequencing the resulting vector using the
Absense primer.
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Table 11. Volumes, cell numbers and cell culture conditions for transfection
Container Volume cells Cell density (M per mL) Shaking (rpm) DNA per chain (µg)
48 well plate 1 mL 0.8 180 0.5
50 mL falcon 10 mL 1.5 180 15
600 mL flask 100 mL 1.5 130 150
7.4.3 Expression of antibodies in a mammalian cell line
HEK-293F cell culture
FreeStyle293-F cells (Invitrogen) were cultured in a volume of 20 mL FreeStyle 293 Expression
Medium at 37 °C and 5% CO2 on a shaker plate at 180 rpm. Every 2-3 days cells were split to a
density of 5x105 cells per mL.
Transfection of HEK-293F cells using polyethylenimin (PEI)
One day prior to transfection, cells were seeded in the appropriate culture container described in
Table 11. On the day of transfection, for 10 mL and 100 mL cultures, the DNA of heavy and light
chain plasmids was added to the culture and the mixture incubated for 5 minutes. 150 µL or 1.5 mL
of PEI solution (0.6 g/L) were then added respectively and the cells returned to culture conditions.
For the 48 well plate, DNA for heavy and light chain was mixed on a sterile 96 well plate with conical
bottom. The PEI solution was diluted 1:8 in FreeStyle 293 medium and 40 µL/well of this dilution
added to the DNA plate. The DNA/PEI mixture was incubated for 5 minutes and transferred to
the cells using a multichannel pipette. The cells were cultured for 24 h and on the next day, one
culture volume of Excell medium was added.
Purification of expressed antibodies
Recombinant antibodies were purified from the cell culture supernatant using Protein G beads for
FastFlow (GE Healthcare). Antibodies were bound to the appropriate amount of beads, calculated
based on the binding capacity, by incubating over night at 4 °C. Beads were harvested by cen-
trifugation and then loaded on empty columns and washed with two column volumes of PBS. The
antibodies were eluted using 0.1 M glycine at pH 3 and re-buffered to pH 7 using 1 M Tris at
pH 9. Purified antibodies were dialysed against PBS using Slide-A-Lyzer Dialysis devices (Thermo
Scientific) according to the manufacturer’s protocol.
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7.5 Antibody testing
7.5.1 Antibody concentration measurement
The antibody concentration of the cell culture supernatant or of the purified antibodies was mea-
sured by enzyme-linked immunosorbent assay (ELISA). 384-well high-binding transparent plates were
coated overnight at 4 °C with 15 µL/well PBS containing 1.66 µL/mL of the goat anti-human IgG
Fc-fragment capturing antibody.
Plates were washed three times with deionized water using a Tecan Plate Washer. 20 µL of blocking
buffer (PBS with 0.05% Tween and 1mM EDTA) were added to the plate and incubated for 1 h at
room temperature to block unspecific binding sites. Again the plate was washed, and 12.5 µL/well of
diluted supernatant or purified antibodies were added. For every measured antibody a 1:2.5 dilution
series of 8 steps was set up starting with an initial dilution between 1:10 and 1:2000 according
to the estimated stock concentration. As a standard, human IgG1 antibody standard of known
concentration was used in a total of 16 dilution steps starting at a concentration of 3 µg/mL.
After 1.5 h of incubation the plate was washed. 15 µL of a horseradish peroxidase (HRP) conjugated
goat anti-human IgG diluted to 0.83 µL/mL in blocking buffer were added to each well and incubated
for 1 h. The ELISA was then washed three times and developed by adding 25 µL/well of ABTS
1-step solution (Roche) previously mixed with 1 µL/mL H2O2. Absorbance was measured at 405 nm
after 5 and 10 minutes on an M1000Pro plate reader (Tecan) using the Magellan software and the
concentration of each sample was calculated from the standard curve.
7.5.2 Antigens
Four different antigens were used for antibody binding assays in this work: ∆N-CSP is a truncated
version of Pf CSP with only amino acids 123-411, i.e. with an N-terminal deletion [101]; NANP10
and NANP5 with 10 or 5 NANP repeat units (Alpha Diagnostic International); NANP3 with 3 NANP
repeat units (PSL GmbH, Heidelberg).
7.5.3 Antigen ELISA
High-binding 384 well plates were coated with different antigens overnight at 4 °C. ∆N-CSP was
used at 10 ng/well, NANP10 at 25 ng/well, NANP5 at 50 ng/well, NANP3 at 82.5 ng/well with 25
µL/well. The plates were washed and blocked with 1% BSA in PBS for 1 h at room temperature.
The sample antibody was diluted in 8 steps of 1:4 starting at 4 µg/mL, transferred to the coated
plate and incubated with the antigen for 1.5 h at room temperature. Bound IgG was detected
using an anti-human IgG-HRP and the corresponding detection kit in the same way as for the
concentration ELISA described in section 7.5.1. The OD value at 405 nm was measured after 5 and
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10 minutes on a Tecan M1000 instrument using the iControl software. The humanized version of
a mouse anti-CSP antibody 2A10 [104] and an isotype control mGO53 [112] were used as positive
and negative control respectively.
7.5.4 Surface plasmon resonance
Surface plasmon resonance measurements were performed on a BIACORE T200 (GE healthcare)
instrument docked with a series S sensor chip CM5 (GE healthcare). 10 mM HEPES buffer with 150
mM NaCl, 0.02 % Tween 20 and 0.05 % BSA at pH 7.4 was used as a running buffer. Anti-human
IgG antibodies were immobilized on the chip using an amine-coupling based human antibody capture
kit (GE Healthcare). In a first step, the concentration of all sample antibodies was determined using
a human IgG1 kappa standard from myeloma plasma. In the second step, equal concentrations
of sample antibody and isotype control were captured in the sample and the reference flow cell,
respectively. Running buffer was injected for 20 min at a rate of 10 µL/min in order to stabilize the
flow cells. NANP5 and NANP3 at 0, 0.015, 0.09, 0.55, 3.3, 20 µM in running buffer was injected at
a rate of 30 µL/min. After each sample antibody the flow cells were regenerated with 3M MgCl2.
The data were fit using a 1:1 binding model in the BIACORE T200 softwareV2.0.
7.5.5 Plasmodium falciparum traversal assay
Cells from a human hepatocyte cell line (HC-04, MRA-975, deposited by Jetsumon Sattabongkot)
were seeded at 6x104 cells/well in a 96-well plate (source) and incubated for 24 h at 37 °C and
5% CO2. 7,500 Pf sporozoites obtained from mosquito salivary glands were incubated with different
concentrations of monoclonal antibodies for 30 min. The mixture was added to the cells in presence
of 0.5 mg/mL dextran-rhodamine. Untreated sporozoites were used as positive control and cells
incubated with only dextran-rhodamine were used to determine the experimental signal background.
After sporozoite addition the plate was centrifuged at 3000 rpm for 10 min without brakes and
incubated for 2 h at 37 °C and 5% CO2. The cells were washed with PBS three times, trypsinized
and resuspended in 10% FCS in PBS. They were then centrifuged as 3600 rpm for 5 min and
the pelet resuspended in 1% PFA in PBS. The percentage of dextran positive, i.e. traversed cells
was measured using a BD LSR II flow cytometer. The background signal was subtracted from
all measurements and the percentage of traversal inhibition calculated at the ratio of the maximal
traversal rate obtained from untreated sporozoites.
7.6 Antibody structure modelling
Computational models of the antibody variable region structure as well as docking models of antibody
to antigen structures were obtained using the Rosetta Antibody software together with a recently
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published protocol [120]. For each antibody 3050 models were generated and the overall score used
to select the best results. Ensemble docking using the Rosetta snugdock algorithm was performed
on these 10 models and the crystal structure of an NANP5 repeat bound to an IGHV3-33/IGKV1-5
antibody (kindly provided by J.-P. Julien). For structural clustering, the 50 best models of each
antibody were selected and pooled for the complete set of antibodies that was supposed to be
analysed. The structures were aligned using the PyRosetta [18] alignment function and the CDR
regions extracted. GOSSIP, a length independent structure alignment algorithm, was used to cluster
the CDR regions [52]. Structural visualization was done using PyMol (V1.8.2.2, DeLano Scientific
LCC, Schro¨dinger). The antibody modelling approach was developed during a research internship
in the laboratory of Prof. William Schief in the course of an EMBO short term fellowship.
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8 Results
8.1 Selection of Pf -experienced donors from CHMI cohort and sorting
of B cell subsets
As part of the investigation of public antibody repertoires in pre-erythrocytic immune responses,
one major aim of the present work was to investigate whether malaria experienced donors from an
endemic area raised or carried similar antibodies as the previously studied European donors after
CHMI. Since previous work showed that naturally acquired antibody responses to pre-erythrocytic
antigens are rare, the present work focused on samples collected during a controlled human malaria
infection in malaria experienced donors. It was speculated that due to an active immune response
during the study, humoral immune responses against the sporozoites and antigen specific B cells
may be easier to detect and isolate.
PBMC samples were collected from a CHMI of donors from a malaria endemic region in Lambare´ne´,
Gabon (LaCHMI, [57]). In a first step the immunity against the parasite infection as well as the
humoral immune response parameters of the LaCHMI participants were assessed in order to choose
donors with signs of protective anti-Pf CSP antibody response for further analysis.
8.1.1 Donors show differences in development of parasitemia and malaria symptoms
LaCHMI participants were infected intravenously with 3,200 sporozoites and monitored throughout
the course of 28 days. Figure 5A shows the overall outcome of the study in terms of blood stage
parasitemia and malaria symptom development. The day of parasitemia is the day on which the
first blood smear was found to be positive, i.e. at least two blood stage parasites were identified
on one slide. The day of drug is the day on which participants were administered the anti-Pf
chemotherapeutic lumefantrine-arethmeter because they had developed malaria symptoms. All five
European control subjects (Pf naive, NA) developed blood stage parasitemia between day 12 and
day 14, as expected for a Pf infection and confirming the validity of the infection protocol. Out
of the 20 Gabonese donors, which were considered to be pre-exposed (PE) because of living in
an endemic area, 12 donors developed blood stage parasitemia between day 13 and day 25. This
prolongation of the prepatency period indicates a higher level of immunity against Pf sporozoite
infection or development of blood stage parasitemia. Some of these donors (e.g. L1-003) even
showed a delayed or absent development of symptoms, a phenomenon known as asymptomatic
parasitemia. 8 Gabonese donors did not develop blood stage parasitemia at all during the course
of 28 days after infection and were thus considered to be protected against the infection due to
naturally acquired pre-existing immunity.
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Figure 5. Selection of LaCHMI donors based on immunological criteria. A: Day of blood
stage parasitema and day of drug treatment for LaCHMI donors. NA: Pf naive, PE: Pf pre-exposed.
B: Anti-Pf CSP IgG and IgM serum titers at days C-1 (one day before infection), D5, D13 and D28.
C: Anti-Pf CSP IgG and IgM serum antibody levels (AUC) on day C-1 as a function of the day of
blood stage parasitemia. D: Difference in anti-Pf CSP IgG and IgM serum antibody levels (AUC)
between Day C-1 and D28 as a function of the day of drug treatment. Donors selected for further
analysis are highlighted in red, blue and green. European donors are shown in black, Gabonese
donors in grey.
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8.1.2 Some donors show anti-Pf CSP serum titers
The focus of the present work is on antibodies directed against the repeat region of the sporozoite
surface protein Pf CSP. In order to choose suitable donors based on the humoral immune response
to Pf CSP, anti-Pf CSP IgG and IgM serum titers were measured at different time points before
and after the sporozoite injection. Figure 5B shows the area under curve (AUC) measured in serum
ELISA against Pf CSP one day before infection (C-1) and 5, 13 and 28 days after infection (D5, D13
and D28). Most of the donors had no measurable or only a weak serum antibody response against
Pf CSP during the course of the study. A clear correlation between anti-Pf CSP serum titers before
injection and the protection level could not be established (Figure 5C). Notably, many donors were
protected against the infection even without measurable Pf CSP serum antibody at C-1. Some of
the donors raise their anti-Pf CSP serum antibody levels during the course of the study (Figure 5B
and D), indicating an active immune response against the sporozoites. Interestingly, the donors
with higher serum reactivity at D28 than on C-1 are also the ones that were treated early on in
the infection (Figure 5D). In donors that do not develop blood stage parasitemia or symptoms the
anti-Pf CSP reactivity even sometimes drops during the course of the study (Figure 5D).
The highlighted donors L1-011, L1-021 and L1-022 were chosen for repertoire sequencing because
they were protected against the infection and showed the highest anti-Pf CSP IgG titers on C-1.
This choice is based on the assumption that common protective anti-Pf CSP antibodies were most
likely found in donors with pre-existing humoral immune memory against Pf CSP.
8.1.3 Heterogeneity in the B cell population dynamics
In order to investigate the dynamics of the B cell response in different donors, the proportions
of different B cell populations as plasmablasts (PB), classical memory B cells (CM) and atypical
memory B cells (AtM) were monitored during the course of the LaCHMI study. Figure 24 (appendix)
depicts the gating strategy chosen to identify cells belonging to the different B cell sub-populations.
The population frequencies are represented in section 13.1.1 (appendix). No correlation between
protection, parasitemia and B cell dynamics could be established. The dynamics of the PB population
were very heterogeneous, with some donors showing none, one or two peaks of high PB frequencies.
The population frequency data was not used to select donors for repertoire sequencing.
8.1.4 Sorting and characterization of plasmablasts, atypical memory B cells and Pf CSP
binding B cells
For the three selected donors L1-011, L1-021 and L1-022 single-cell sorting of different B cell
populations was performed in order to sequence paired heavy and light immunoglobulin chains and
characterize the Pf CSP specific antibody repertoire. Fluorescently labelled full-length Pf CSP was
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Figure 6. Gating strategy for isolation
of CSP binders, plasmablasts and atypi-
cal memory B cells from CD19+ B cells.
The B cell gate is pre-gated on single live lym-
phocytes using side and forward scatter as well
as the live/dead stain 7-AAD. Data shown for
donor L1-021 on day D7.
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used as a bait to isolate Pf CSP binding B cells. In addition Pf CSP specific B cells are expected
to be activated and differentiate into antibody secreting plasmablasts after the sporozoite injection.
They can be found in the blood 7-10 days after first antigen encounter but since they loose BCR
surface expression, they are inaccessible to identification with a fluorescently labelled antigen bait.
In contrast the role of AtM B cells remains controverse, but it has nevertheless been shown that
they can be specific to malaria antigens [34, 66]. In order to isolate potential Pf CSP specific B cells
in the PB (CD19+, CD27+, CD38+) and AtM B cell population (CD19+, CD21-, CD27-), these
two populations were specifically sorted at D7 and D13 after infection. The detailed gating strategy
for donor L1-021 on D7 is depicted in Figure 6.
Figure 7A confirms that the AtM B cells share characteristics of previously observed atypical subsets,
as notably elevated surface expression of CD19 and CD20 in comparison to CM B cells and partial
IgG surface expression. Interestingly, the frequency of AtM B cells was higher in the Pf CSP binding
B cell population than in the overall B cell population in most of the samples (Figure 7C). The AtM
B cells enriched in the Pf CSP binding compartment share the same phenotype as the overall AtM
population (Figure 7B).
The previous observations and results thus allowed to select three donors out of the Gabonese CHMI
cohort based on signs of pre-existing humoral immunity to Pf CSP. Moreover analysis of the B cell
populations used for single-cell sorting revealed that AtM B cells are enriched in the Pf CSP antigen
specific B cell population.
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Figure 7. Enrichment of atypical memory B cells in the Pf CSP binding population.
A: CD19, CD20 and IgG surface expression of atypical memory (AtM) and classical memory (CM)
B cells pre-gated on all CD19+ B cells. B: CD19, CD20 and IgG surface expression of AtM and CM
B cells pre-gated on Pf CSP binding B cells. C: Frequency of AtM in CD19+ B cells against AtM
in Pf CSP binding B cells.
Table 12. Constant primers in Roche454 [68] setup and Illumina setup
Locus PCR reaction Roche454 constant primers Illumina constant primers
IGKC 1st PCR hIGKC-220-Rv hIGKC-172-Rv
2nd PCR hIGKC-172-Rv hIGKC-032-Rv
IGHA 1st PCR hIGHA-140-Rv hIGHA-111-Rv
2nd PCR hIGHA-111-Rv hIGHA-076-Rv
IGHG 1st PCR hIGHG-137-Rv hIGHG-137-Rv
2nd PCR hIGHG-084-Rv hIGHG-074-Rv
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8.2 Sequencing and computational annotation of B cell repertoires
In order to be able to compare the Pf CSP specific antibody repertoires, the immunoglobulin tran-
scripts of the sorted B cells needed to be amplified, sequenced and annotated. In general the
previously published method [16] relies on a matrix of 384-well plates into which single cells are
sorted well-wise. A high-throughput automation platform is used to perform massive-parallel reverse-
transcription PCR reactions on single-cell level. The resulting amplicons are pooled for next genera-
tion sequencing. Due to the discontinuation of the Roche 454 sequencing platform, the established
human transcript amplification method [68] had to be adapted to an Illumina sequencing platform.
In addition a bioinformatics pipeline had to be established to analyse the sequencing results.
8.2.1 Generation of immunoglobulin amplicons for Illumina sequencing
The longest read lengths that can be sequenced and reliably assembled using the Illumina technology
are around 550 bp and can be achieved using the Illumina MiSeq 300bp-300bp paired end sequencing
protocol. To adapt the previous Ig transcript amplification method to Illumina sequencing, one major
step was to develop new primer sets to reduce the length of the amplicons, which was previously
up to 600 bp. Notably the 3’ primers specific for constant regions IGHG, IGHA and IGKC had to
be replaced, whereas the 5’ primers specific for the variable region were not modified (Table 12).
Figure 8 shows the comparison of amplification efficiencies between the old primer sets as published
in [68] and the primers developed for the new sequencing approach. The amplification efficiency,
i.e. the percentage of successfully amplified transcripts assessed by gel electrophoresis, could be
maintained or sometimes even increased with the new primer sets.
Also, since Illumina sequencing requires unconventional Y-shaped sequencing adaptors, the new
primer sets did not include the sequencing adaptors any more as opposed the previous approach [16].
The adaptors were instead ligated to the amplicons during library preparation using a Illumina TruSeq
PCR-free library prep kit.
8.2.2 Development of a computational tool for single-cell level B cell repertoire analysis
To analyse the raw sequencing data provided by the Illumina MiSeq instrument a new computational
analysis tool was developed under the name of ”Single cell immune Repertoire tool-kit” (sciRep-
tor, [47]). The role of the program is to map single reads to the wells they originated from by
identifying paired tag sequences. It also annotates standard immunoglobulin characteristics as gene
segment usage, mutational status, isotype and others. The data and annotations are stored in a
relational database.
The first step in the computational analysis is to determine which immunoglobulin chain (heavy (H),
kappa (K) or lambda (L)) is encoded by each sequence and to identify the forward and reverse tags
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Figure 8. PCR efficiencies of
the primer sets published in [68]
compared to the newly devel-
oped primer sets for generation
of shorter fragments, as shown
in Table 12. Efficiency was
tested on sorted Igκ+ memory B
cells (IGK), sorted IgA+ memory B
cells (IGHA) or sorted IgG+ mem-
ory B cells (IGHG). The amplifica-
tion efficiency represents the per-
centage of successfully amplified
transcripts (assessed by gel elec-
trophoresis) within the total set of
amplification reactions.
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that are necessary to locate the well of origin of each sequence. IgBLAST [126] is used for locus
annotation, whereas RazerS [118] is used for tag finding. The statistics of tag identification for one
exemplary run are shown in Figure 9A. 807,256 raw sequencing reads went into the analysis of which
485 failed to be attributed to a specific locus. Between 208,000 and 315,000 reads were associated
to the three loci and between 40 and 80% of these had a successful identification of both tags. The
relatively low level of tag identification especially for the L locus is due to sequencing errors in the
tag region or due to sequencing of amplicons that were amplified with primers originating from the
first PCR reaction and thus not containing sequence tags.
After successful identification of the sequence tags, sciReptor assembles all reads belonging to a
certain well and locus and builds consensus sequences using MUSCLE sequence alignment [27]. Since
B cells sometimes have two immunoglobulin transcripts from independent recombination events, the
algorithm first assembles the sequences mapped to the most abundant V-J combination to build a
first consensus. In the following step, the second most common V-J combination is treated similarly.
Figure 9B depicts the statistics of first and second consensus and their respective reads per well
numbers (red and blue curve). The histogram shows the overall distribution of reads per well. A
consensus is only built if more than 5 sequences are assigned to the well. The fact that the first
consensus clearly has the majority of sequences per well confirms the validity of sequencing and
consensus building approach.
Figure 9C finally represents the spatial distribution of sequencing success on the 12 384-well plates
belonging to one matrix processed by the automation platform. Every black square on the matrix
represents a successful identification of the corresponding sequence. In the case of the depicted
experiment the success rate of sequencing the heavy and corresponding light chain was 54%. Notably,
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the efficiencies obtained after computational sequence analysis are comparable to those measured
by counting the PCR positive wells on an agarose gel, confirming that the computational approach
is suited for the analysis of the single-cell repertoire sequencing data.
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Figure 9. Quality control for the successive steps of the computational analysis of reper-
toire sequencing data. A: Statistics of identification of proximal and distal tags for H, K and L
chains. B: Reads per well statistics for all sequences (histogram), sequences assigned to 1st consensi
(red) and sequences assigned to 2nd consensi (blue). C: Spatial representation of the 12 384-well
plates belonging to one processing matrix. Black squares indicate successful sequencing of the H,
K or L immunoglobulin transcript.
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8.3 Public repertoire of Pf CSP-reactive antibodies is restricted to Euro-
pean donors
Once the methodology for repertoire sequencing was established, the immunoglobulin transcripts of
the different B cell populations from the Gabonese donors were sequenced and annotated. In order to
identify clusters of public repertoire in the CSP-specific repertoire of Gabonese and European donors,
the antibody sequences were compared regarding their amino acid sequence similarity. Pairwise full-
length alignments were performed with sequences between the start of CDR1 and the end of the J
segment. The sequence homology was calculated as the ratio of Hamming distance divided by the
length of the alignment. A graph was built from the similarity matrix obtained from the pairwise
alignments. In this graph, nodes correspond to single antibodies, i.e. paired heavy and light chain
sequences. Edges have two weight attributes: sequence similarity on heavy chain level and sequence
similarity on light chain level. Table 13 summarizes the two different data sets that went into the
analysis.
8.3.1 Community clustering approach identifies small and diverse clusters of similarity
In order to identify public antibodies with similar sequence characteristics, the analysis was further
focused on single groups of similar antibodies. To this purpose the graph generated during compu-
tation of similarity distributions was reduced to a set of subgraphs with an edge weight of at least
90% in heavy and light chain.
Figure 10 shows a selection of the biggest repertoire clusters identified using the clustering approach
and grouped according to the utilized heavy chain variable gene. Every unit on the circles represents
one antibody sequence belonging to the different Gabonese LaCHMI and European TuCHMI donors.
Lines indicate a sequence similarity of more than 90% on amino acid level in heavy and light variable
region. It can be observed that the clusters are small and diverse, utilizing a great variety of different
V segments. Nevertheless an utilization of IGHV genes from the IGHV3 and IGHV4 family seems to
be preferred, most importantly IGHV3-23, IGHV3-33 and IGHV4-59. The public repertoire clusters
are more often shared between European than between Gabonese donors.
Table 13. Dataset used for the analysis of repertoire similarities
Dataset Description
TuCHMI 2600 paired H+L chain sequences
Data from 5 European donors
Pf CSP binders (non mature naive) and plasmablasts sorted from PBMCs [69]
LaCHMI 1012 paired H+L chain sequences
Data pooled from 3 Gabonese donors
Pf CSP binders, plasmablasts and atypical memory B cells sorted from PBMCs
46
Clusters with Kappa
light chain
Clusters with Lambda
light chain
European
Gabonese
IGKV1
IGKV2
IGKV3
IGKV4
Heavy paired with:
IGLV1
IGLV2
IGLV3
IG
H
V3
-2
3
IG
H
V3
-2
3
IG
H
V3
-3
3
IG
H
V3
-4
8
IG
H
V3
-2
1
IG
H
V3
-2
1
IG
H
V4
-5
9
IG
H
V4
-5
9
IG
H
V3
-7
4
IG
H
V4
-3
9
Figure 10. Selection of clusters of similarity with >90% amino acid homology in heavy and
light chain. Every unit of the circle represents one antibody sequence, grouped by European (dark
grey) and African (light grey) donors. Connecting lines represent an amino acid homology of >90%
in heavy and light chain. Left column: Clusters utilizing Igκ light chains. Right column: Clusters
utilizing Igλ light chains. Colours encode the family of the utilized light chain variable gene.
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8.3.2 Antibody cloning based on sequence similarity identifies clusters of similar binding
only in European repertoire
In order to investigate, whether the clusters of sequence similarity identified in the previous step also
represent groups of functional similarity, the binding behaviour of selected members was assessed.
Pf CSP reactivity data was either taken from a previous study [69] or assessed by cloning, expressing
and Pf CSP ELISA reactivity assessment of additional antibodies. To focus on antibodies against
Pf CSP, clusters where at least one member bound Pf CSP in FACS sorting were chosen. Another
criteria for the cluster selection was that they were shared by two donors at least.
Figure 11 shows a representative selection of sequence similarity based reactivity prediction results.
Within most of the clusters the tested antibodies show similar reactivities, i.e. either binding to ∆N-
CSP in ELISA above a defined threshold (AUC >1) or not. However, antibodies from Gabonese
donors clustering together with reactive antibodies from European donors, as in cluster 83, fail to
show measurable Pf CSP reactivity. In general, the reactivity prediction approach works well for
European donors but not for Gabonese donors. No antibodies from Gabonese donors could be
identified that bound Pf CSP.
8.3.3 Antibody cloning based on sequence annotation fails in Gabonese repertoire
In order to exclude that the Pf CSP antibodies in the public Gabones repertoire are too highly
mutated to have enough sequence similarity to the European germline like antibodies, predictive
cloning was also performed based on more general sequence features. It has e.g. previously been
shown that IGHV3-33 is enriched in the high-affinity Pf CSP binding antibodies as well as antibodies
with a short KCDR3 of 8 amino acids. A set of 10 antibodies with either of these sequence features
were thus cloned from the Gabonese donors, expressed and tested in antigen ELISA. None of them
bound Pf CSP in ELISA.
For one specific antibody utilizing IGHV3-33 and IGKV1-5 with a KCDR3 region of 8 amino acids, it
was investigated whether somatic hypermutations could have abolished Pf CSP binding. A molecular
model of the antibody was generated and the positions of somatic hypermutations leading to amino
acid exchanged investigated [78]. However even when reverting the relevant mutation at position
H.58, no Pf CSP binding could be observed, indicating that the antibody even in it’s germline
configuration was not Pf CSP reactive.
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Figure 11. Predictive cloning based on identified clusters of similarity. Cluster number indi-
cated in bold. Every node represents one antibody, i.e. paired heavy and light chain immunoglobulin
sequences. The number inside the node represents the event identifier attributed by the analysis
software. The shape of the node represents the donor from which the sequence was isolated. Grey
lines connect antibodies with >90% amino acid similarity in heavy and light chain. Nodes corre-
sponding to cells that bound CSP in FACS have a red border. The color fill indicates reactivity in
ELISA (reactive: AUC >1).
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8.3.4 Cloning of antibodies from Gabonese repertoire based on Pf CSP binding in FACS
does not identify binders
Surprisingly none of the two previous predictive cloning approaches lead to identification of binding
antibodies in the Gabonese donors. Since the donors nevertheless were selected based on their
anti-Pf CSP titers and also showed Pf CSP specific memory B cells in FACS sorting, it was however
assumed that CSP specific memory B cells were present in the isolated populations. A last selection
of cells was thus made based on Pf CSP binding during FACS sorting, and the corresponding set
of 41 antibodies cloned and tested in antigen ELISA. The CSP binding of the corresponding B
cells in FACS as well as their isotype determined in sequencing are depicted in Figure 12A and B.
The majority of the antibodies is of the IgM isotype, an observation that has previously also been
made for the Pf CSP specific antibodies of European donors [69]. None of these antibodies showed
Pf CSP-binding in ELISA12C, which could mean that their affinity to Pf CSP was not high enough
or that the antibodies were not at all specific for Pf CSP.
In the Gabonese donors, none of the here described cloning attempts lead to successful identification
of antibodies with measurable Pf CSP reactivity in ELISA. However, the similarity clustering as well
as the prediction of Pf CSP binding based on sequence similarity gave satisfying results for the
antibody repertoires of the European CHMI donors. Several clusters of highly Pf CSP reactive
antibodies were identified and shared between different donors.
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Figure 12. Antibodies cloned from B cells sorted using a fluorescently labelled Pf CSP
bait. A: Pf CSP binding in FACS. Cells with transcripts selected for cloning are shown in red.
All sorted cells are shown in grey. B: Isotype distribution of the transcripts selected for cloning.
C: Pf CSP ELISA reactivity of cloned antibodies shown in grey. 1349 (red) is a positive control
antibody presented in section 8.4.1.
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8.4 Molecular characterisation of binding modes in public antibodies
The last part of the present work focuses on describing the molecular Pf CSP-repeat binding char-
acteristics of common CSP-reactive antibodies isolated from the European CHMI donors. Under-
standing the molecular determinants of these antibodies, that were raised during repeated controlled
sporozoite injection, could eventually lead to a better understanding of why such antibodies are not
found after natural parasite exposure.
Two groups of antibodies with very low levels of somatic hypermutations (<5 amino acid exchanges
from germline) and high Pf CSP reactivity were selected for molecular characterization and compar-
ison:
• Antibodies with an Igλ chain utilizing IGLV1-47 and a LCDR3 region of 11 amino acids. The
heavy chains are encoded by different heavy chains, raising the question whether the binding
mode is similar and whether the light chain plays a similar role in all antibodies.
• Antibodies with an Igκ chain utilizing IGKV1-5 and a particularly short KCDR3 of 8 amino
acids. Again different IGHV genes are used.
8.4.1 Comparison of CSP binding of antibodies utilizing IGLV1-47 but different IGHV3
variable genes
Assessment of antibody structure similarity by homology modelling
The first set of selected antibodies shares highly similar or even identical Igλ chains but utilize the
heavy chain variables genes IGHV3-48 or IGHV3-23 (Figure 13A). In order to assess the structural
similarity of the antigen binding site in these antibodies, computational homology modelling was
performed for each antibody variable region. The 50 best structure models for every antibody
obtained by Rosetta homology modelling were selected and pooled. Structural clustering of the CDR
regions was performed based on a length-independent global structure alignment algorithm [52].
By applying this procedure to the pool of structure models, antibody models with similar CDR
conformations were clustered, in order to detect a similar conformation spectrum of the antibodies
that were modelled. Figure 13B depicts the size distribution of the resulting structural clusters. All
antibodies encoded by IGHV3-23 have models that cluster together in the biggest cluster (Nr. 0),
indicating a convergence in structural modelling (Figure 13C). However the two antibodies utilizing
IGHV3-48 have fewer (1349) or no models (121) in cluster Nr. 0, but still cluster together in Cluster
Nr. 1. The structural similarity within the IGHV3-23 encoded antibodies thus seems to be greater
than between the antibodies encoded by different IGHV genes.
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Figure 13. IGLV1-47 utilizing antibodies and their structural similarity assessed by molec-
ular modelling. A: Sequence properties of selected public antibodies utilizing IGLV1-47. Gene
usage, somatic hypermutation counts as well as Pf CSP binding of corresponding B cells in FACS
is indicated. All cloned antibodies were reactive to the repeat region of Pf CSP in ELISA. B: Size
distribution of the clusters of structural similarity obtained by applying a global structure alignment
algorithm to a pool of the 50 best structure models for every antibody. Parameters for GOS-
SIP clustering: alignment length threshold 0.95, maximal distance between two matching Cα 1.5
A˚. C: Contribution of models from the different antibodies to the clusters of structural similarity.
Cluster IDs are assigned according to the size of the cluster.
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Both clusters show similar sensitivity for major changes in the lambda chain
Experiments introducing major changes in the lambda chain showed that the LCDR3 length as
well as the sequence of the IGLV1-47 segment play a role in antigen binding of the here probed
antibodies (Figure 14). When replacing the light chain of antibody 1349 with a highly mutated
IGLV1-47 encoded light chain isolated from a Gabonese donor, repeat binding was lost, although
the LCDR3 was still 11 amino acids long ( alt l11, Figure 14A). Similarly, when pairing the heavy
chain of 1349 with and unmutated IGLV1-47 utilizing light chain with 12 amino acids, binding was
lost (Figure 14A). Similar observations were made for antibodies 121, 982 and 1015 which are other
representative antibodies utilizing IGHV3-48 or IGHV3-23 (Figure 14A).
Effect of affinity maturation and recombination sequence of the light chain is dependent
on the heavy chain sequence
The loss of binding when paired with a highly mutated IGLV1-47 encoded light chain already
highlighted the importance of the exact amino acid sequence of the Igλ chain. Interestingly, one
of the antibodies utilizing IGHV3-48, antibody 1349, shows an amino acid replacement in the Igλ
chain at residues L.33 and an alternative LCDR3 region that differs in one amino acid due to
recombination differences (Figure 15A). These residues are not part of the antibody surface as
indicated by molecular modelling (data not shown) and thus most likely have a stabilizing effect
on surrounding residues that directly interact with the antigen. In order to investigate what effect
these replacements had on the other antibodies, a set of heavy chains utilizing either IGHV3-48 or
IGHV3-23 were paired with the affinity matured light chain l1349 (Figure 15B). NANP10 binding
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Figure 14. Importance of the LCDR3 length and sequence for IGLV1-47 utilizing anti-
bodies. A: NANP10 antigen ELISA with 1349 wildtype and chimeric antibodies with 1349 heavy
chain and mutated IGLV1-47 utilizing light chain with 11 amino acid long LCDR3 (alt l11) and
IGLV1-47 utilizing light chain with 12 amino acid long LCDR3 (l12). B: Loss of NANP10 binding in
antigen ELISA due to light chain replacement in 1349, 121, 982 and 1015 antibodies.
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of 121, another antibody utilizing IGHV3-48 was not affected or even slightly improved, whereas
both antibodies utilizing IGHV3-23 (982 and 1015) showed reduced binding. As expected, when
replacing the mutated lambda chain of 1349 with a germline encoded lambda chain, the AUC was
reduced. This shows that the effect of affinity maturation and recombination sequence in the 1349
light chain is dependent on the heavy chain and thus beneficial only for antibodies utilizing the same
IGHV gene.
Overall, the results obtained for common anti-Pf CSP antibodies utilizing IGLV1-47 and different
IGHV genes demonstrate a common requirement of the Igλ sequence to maintain the overall binding
mode. However, the exact antigen binding mode and the effect of single amino acid replacements
depend on the sequence of the heavy chain, indicating differences in single residue interactions.
8.4.2 Germline recombination of common anti-Pf CSP antibodies utilizing IGHV3-33
Antibodies belonging to another important set of public antibodies utilize IGHV3-33 and IGKV1-5
genes with a KCDR3 length of 8 amino acids (VH3-33/Vκ1-5/KCDR3:8). They have a considerable
affinity to the repeat antigen, as measured by surface plasmon resonance (SPR) although low levels
of somatic hypermutations (Figure 16A). The following results highlight the importance of germline
recombination events as well as polymorphisms in the IGHV locus for the generation of these
common anti-Pf CSP antibodies.
Vλ1-47 QSVLTQPPSASGTPGQRVTISC SGSSSNIGSNYVY WYQQLPGTAPKLLIY RNNQRPS GVPDRFSGSKSGTSASLAISGLRSEDEADYYC AAWDDSLSG
l121
l982 QSVLTQPPSASGTPGQRVTISC SGSSSNIGSNYVY WYQQLPGTAPKLLIY RNNQRPS GVPDRFSGSKSGTSASLAISGLRSEDEADYYC AAWDDSLSGVV FGGGTKLTVL
l1015
l1349 QSVLTQPPSASGTPGQRVTISC SGSSSNIGSNYLY WYQQLPGTAPKLLIY RNNQRPS GVPDRFSGSKSGTSASLAISGLRSEDEADYYC AAWDDSLSGPV FGGGTKLTVL
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Figure 15. Effect of affinity maturation and light chain recombination on antibody binding
is dependent on the heavy chain sequence. A: Sequence alignments of the light chains of
antibodies 1349, 121, 982 and 1015. Amino acid exchange due to somatic hypermutation is shown
in red. Green: Sequence difference due to alternative VJ recombination. B: CSP reactivity of
antibodies 1349, 121, 982 and 1015 as well as chain swap chimeras utilizing 1349l chain and 121l
chains.
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IGKV gene usage and recombination are essential for antigen binding
Several experiments with chimeric antibodies were conducted to investigate the role of the Igκ
chain for antigen binding of VH3-33/Vκ1-5/KCDR3:8 antibodies. When replacing the light chain of
representative VH3-33/Vκ1-5/KCDR3:8 antibodies 1210 and 2219 by light chains of either same Vκ
segment but longer KCDR3 region the binding was abolished (Figure 16B). Similarly, when replacing
the kappa chain of 2219 with a kappa chain with same CDR3 length but utilizing the IGKV2-28
gene the binding was abolished (Figure 16B).
Moreover when creating chimeric antibodies by swapping Igκ chains within the cluster of VH3-
33/Vκ1-5/KCDR3:8, it was found that part of the antigen binding is encoded in the KCDR3
sequence. When replacing the affinity matured Igκ chain of antibody 2140 with other mutated
(1210k) or unmutated (2243k) Igκ chains with different recombination sequence (Figure 16D), the
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Figure 16. VH3-33/Vκ1-5/KCDR3:8 are high-affine germline-like antibodies and their
Pf CSP binding depends on the Kappa CDR3 length and sequence. A: NANP5 affinity
measured by SPR versus SHM counts for anti-Pf CSP antibodies reported in [69]. Antibodies
encoded by IGHV3-33 and IGKV1-5 with 8aa-long CDR3 (VH3-33/Vκ1-5/KCDR3:8) are high-
lighted in green. Representative antibodies are labelled. B: CSP ELISA reactivity of VH3-33/Vκ1-
5/KCDR3:8 antibodies 1210 and 2219 with original Igκ chain (solid lines) or after Igκ replacement
(dashed lines) encoded by IGKV2-28 with 8aa-long KCDR3 (IGKV2-28 l8) or IGKV1-5 with 9aa-long
KCDR3 (IGKV1-5 l9). C: NANP5 affinity measured by SPR of 2140 antibody and 2140h 1210k and
2140h 2243k chimeras. * p < 0.05, ** p < 0.01, one sided Mann-Whitney test. D: Sequences of
2140, 2243 and 1210 Igκ chains compared to Vκ1-5 germline. The KCDR3 region is shown in pink.
Mutated residues are bold and underlined.
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affinity could be increased significantly (Figure 16C). This data also demonstrates that in order to
generate high antigen binding affinities, kappa chain germline recombination can be more important
than affinity maturation, as shown by the higher affinity of 2140h 2243k compared to 2140.
A specific residue encoded in IGHV3-33 is essential for the generation of these antibodies
IGHV3-33*01, the allele utilized in all antibodies of the VH3-33/Vκ1-5/KCDR3:8, strongly resembles
other IGHV3 genes, differing by only one or two amino acid in HCDR2 at positions 50 and 52
(Figure 17A). Residues W52 is exchanged to S or R in IGHV3-30-3 and some alleles of IGHV3-
33, IGHV3-30 and IGHV3-30-5. Residue V50 is replaced by F in some alleles of IGHV3-30-5 and
IGHV3-30. Using site directed mutagenesis the residues at positions 50 and 52 in antibodies 2140,
1210, 2163, 2219 and 2290 were replaced by the other variants. All tested mutants lost binding to
CSP in ELISA (Figure 17B) as well as inhibition potential in Pf traversal experiments (Figure 17C).
The presence of the correct allele of IGHV3-33 in the IGHV locus thus seems to be essential
for the generation of VH3-33/Vκ1-5/KCDR3:8 antibodies. Since it has been reported that some
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Figure 17. Dependence of VH3-33/Vκ1-5/CDR3 antibodies on specific IGHV3-33 gene.
A: HCDR2 residues 50-52A encoded by different IGHV3-33, IGHV3-30, IGHV3-30-3 and IGHV3-
30-5 alleles. Green: IGHV3-33 allele of VH3-33/Vκ1-5/CDR3 anti-Pf CSP antibodies. Purple:
Polymorphic residues. B: CSP ELISA reactivity of the indicated antibodies (solid lines) and respective
mutants (dashed lines) at position H.V50 and/or H.W52. C: Mean Pf liver cell traversal inhibition
for the indicated antibodies and respective H.W52 mutants compared to a non Pf CSP-reactive
isotype control. Dots represent independent experiments.
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human haplotypes lack this gene, genomic sequencing of all CHMI donors was used to investigate
their genetic predisposition for common anti-Pf CSP antibodies. The frequencies of IGHV3-33* like
germline IGHV segments in TuCHMI and LaCHMI donors are represented in Figure 18. Within the
TuCHMI cohort, one of the patients that failed eliciting VH3-33/Vκ1-5/KCDR3:8 antibodies was
also found to lack the germline gene for IGHV3-33 (Figure 18A, T2 051). However one TuCHMI
donor and all three LaCHMI donors for which repertoire sequencing was performed, had IGHV3-
33 in their germline genes but failed to mount the VH3-33/Vκ1-5/KCDR3:8 antibody response
(Figure 18A and B), indicating that the presence of a certain germline gene is not sufficient to
induce the corresponding antibody response.
Overall the data demonstrates that not only length and sequence of the Igκ chain recombination
are crucial for binding of VH3-33/Vκ1-5/KCDR3:8, but also utilization of a very particular variable
gene segment of the IGHV3 family.
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IGHV3-30/IGHV3-30-3
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VH3-33/Vκ1-5/KCDR3:8 
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Figure 18. Genomic sequencing of IGHV3-33*-like germline genes in CHMI donors. The
bars indicate the proportion of IGHV3-33 (blue), IGHV3-30/IGHV3-30-3 (grey) and IGHV3-30-5
(black) sequences within the IGHV3-33*-like sequences (classification according to Figure 17A). A:
Sequencing of IGHV3-33*-like genes from DNA extracted from whole blood for analysed TuCHMI
donors. VH3-33/Vκ1-5/KCDR3:8 anti Pf CSP antibodies were only identified in 5 out of 8 donors.
B: Sequencing of IGHV3-33*-like genes from DNA extracted from sorted mature naive B cells of
LaCHMI donors.
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Heterogeneity in the CDR conformation of VH3-33/Vκ1-5/CDR3 antibodies
Binding in the cluster of VH3-33/Vκ1-5/CDR3 is thus strongly constrained by sequence features,
that are partly dependent on genetic predisposition. Interestingly the HCDR3, whose sequence is
usually very relevant for antigen binding, did not show any obvious motifs or sequence signatures
raising the questions of structural conformation of the HCDR3 loop in the set of antibodies.
Molecular homology modelling using Rosetta antibody was used to investigate the conformational
landscape of the antibodies. In contrary to what was previously observed for the public IGLV1-47
antibodies, there was no clear convergence of CDR conformations in the VH3-33/Vκ1-5/CDR3
antibodies, even when using broader clustering parameters (Figure 19). The size distribution of
structure similarity clusters is broad and there is no cluster with a contribution of all antibodies,
suggesting a rather broad variety of different CDR conformations within the set of VH3-33/Vκ1-
5/CDR3 antibodies. This observation is indeed also supported by crystallization experiments of a
representative VH3-33/Vκ1-5/CDR3 antibody, 1210, with a NANP-repeat epitope (data not shown,
crystal structure kindly provided by J.-P. Julien). In the contact between antibody and antigen, the
HCDR3 region is only involved by Cα mediated interactions. Conformational differences in the
HCDR3 region could thus be less relevant for antigen binding, as long as the framework provided
by KCDR3, HCDR1 and HCDR2 mediates binding.
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Figure 19. Structural clustering results for VH3-33/Vκ1-5/KCDR3:8 antibodies. A: Size
distribution of clusters obtained by GOSSIP clustering. Parameters for GOSSIP clustering: alignment
length threshold 0.95, maximal distance between two matching Cα 3.0 A˚. B: Contribution of models
from different antibodies to clusters of structural similarity.
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8.4.3 Identification of a particular binding mode in IGHV3-33 utilizing antibodies me-
diated by the tandem-repeat organisation of Pf CSP
Affinity maturation is the process that optimizes binding of a B cell receptor to an antigen in a
specific binding conformation. If different antibodies share the same binding mode, they should
also share similar patterns of affinity maturation. Strong selection patterns were identified when
aligning all sequences of the VH3-33/Vκ1-5/KCDR3:8 antibody cluster. Replacement mutations
were over-represented in the IgH V gene at positions 31, 50 and 56 as well as in the Igκ V gene at
position 93 (Figure 20A). In order to quantify the selection acting at these positions, a computational
hypermutation model was used to generate a set of sequences with similar mutation loads as the
observed VH3-33/Vκ1-5/KCDR3:8 set [37, 125]. When comparing the amino acid usage of the
Pf CSP binders (obs) to the reference set (base), a selection of the following replacements became
apparent: H.S31N, H.V50I/L, H.N56K/H, K.N93S/N (Figure 20B).
In order to assess the effect of these mutations on affinity maturation, mutants and reversions of
two representative antibodies, 1210 and 2163, were generated (section 13.2, appendix). The mutant
antibodies were recombinantly expressed and their affinity towards the NANP3 antigen measured in
surface plasmon resonance. Exchanges H.S31N, H.V50I were associated with affinity increase against
the core epitope in both 1210 and 2163 antibodies (Figure 21). Indeed, the direct involvement of
residues at positions H.31 and H.50 was also confirmed in the 1210-NANP5 co-crystal structure
(data not shown, crystal structure kindly provided by J.-P. Julien).
However, mutations H.N56K or K.S93N did not lead to significant changes in affinity (Figure 21).
Exchanges at positions H.N56 and K.S93 are not selected due to an improved antigen binding by
direct interactions with the NANP-repeat peptide. Crystallization of 1210 bound to NANP5 revealed
that residues H.K56 or K.N93 are involved in direct interactions of the paratopes of two antibodies
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Figure 20. VH3-33/Vκ1-5/KCDR3:8 affinity maturation. A: SHM counts in IgH (top) and
Igκ (bottom) chains (n=63). Bars represent the number of silent (grey) and replacement (red)
mutations in shaded FWRs (grey) and CDRs (pink) defined according to Kabat scheme. Positions
of frequent amino acid exchanges are indicated. B: Observed (obs) aa usage at positions H.31,
H.50, H.56 and K.93 compared to a computational baseline model of SHM (base; [37, 125]).
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Figure 21. VH3-33/Vκ1-5/KCDR3:8 affinity maturation only partially increases affinity
to NANP-repeat. A, B: NANP3 affinity measured by SPR for antibodies 1210 (A) and 2163
(B) and the indicated mutants (Section 13.2, Appendix). Dots represent independent experiments.
Multiple testing with Bonferroni correction: ** p <0.01, ns: not significant.
binding to neighbouring epitopes in the NANP5 peptide (data not shown, crystal structure kindly
provided by J.-P. Julien). This binding mode can be described as paratope-antigen-paratope binding
(or sandwich binding) and involves affinity maturation that increases the affinity of a complex
antibody-antigen -antibody assembly.
Overall the results on affinity maturation confirm the hypothesis of a common binding mode within
the complete set of VH3-33/Vκ1-5/KCDR3:8 antibodies, since similar selection patterns can be
observed in all antibodies. Moreover, anti-idiotope affinity maturation is observed due to a common
paratope-antigen-paratope binding mode, that is enabled by the repetitive structure of the NANP-
repeat.
8.4.4 Antibodies encoded by IGHV3-23 have the same sandwich binding mode as
IGHV3-33 encoded antibodies
Affinity maturation in VH3-23/Vκ1-5/KCDR3:8 antibodies at positions H.56 and K.93
Anti-idiotope affinity maturation patterns similar to the ones described in VH3-33/Vκ1-5/KCDR3:8
antibodies could also be observed in a set of public antibodies defined by the utilization of IGHV3-
23 instead of IGHV3-33. Despite the differences between the two IGHV genes, it appears that the
binding mode of both types of antibodies is somewhat similar. The antibodies from the IGHV3-23
cluster have a higher mutation load and lower repeat affinity (Figure 22C) but nevertheless there
is a strong selection for amino acid exchanges at positions H.56 and K.93 (Figure 22A). When
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Figure 22. Affinity maturation in common VH3-23/Vκ1-5/KCDR3:8 antibodies. A: SHM
counts in IgH (top) and Igκ (bottom) chains (n=24). Bars represent the number of silent (grey) and
replacement (red) mutations in shaded FWRs (grey) and CDRs (pink) defined according to Kabat
scheme. Positions of frequent amino acid exchanges are indicated. B: Observed (obs) aa usage at
positions H.56 and K.93 compared to a computational baseline model of SHM (base; [37, 125]). C:
NANP5 affinity measured by SPR versus SHM counts for anti-PfCSP antibodies reported in [69].
Antibodies encoded by IGHV3-23 and IGKV1-5 with 8aa-long CDR3 (VH3-23/Vκ1-5/KCDR3:8)
are highlighted in green. Representative antibody 1450 is labelled.
analysing the amino acid usage at these positions, residues with longer polar side chains appear
to be selected at both positions. This is similar to what was observed in the IGHV3-33 utilizing
antibodies (Figure 22B).
Binding mode confirmed by molecular modelling
In order to investigate whether these similar affinity maturation patterns were also due to a similar
binding mode, the conformation of antigen binding to VH3-23/Vκ1-5/KCDR3:8 antibodies was
assessed in order to compare it to the one known for VH3-33/Vκ1-5/KCDR3:8 antibody sandwich
binding. Molecular modelling followed by computational docking of the NANP5 repeat was performed
for the representative VH3-23/Vκ1-5/KCDR3:8 antibody 1450. As a control for the validity of the
method, the same was also done with the representative VH3-33/Vκ1-5/KCDR3:8 antibody 1210
that had been crystallized before in complex with the antigen (structure kindly provided by J.-P.
Julien). Figure 23A shows a comparison of the best resulting homology models for 1210 and 1450
antigen binding compared to the crystal structure of 1210-NANP5. The overall antigen binding
mode of 1210 and 1450 is very similar.
Figure 23B compares the antibody residues that interact with the antigen in the crystal struc-
ture as well as the two docking models. The major differences in residues binding the antigen are
observed in the HCDR2 and HCDR3 which are also the regions with highest levels of sequences
dissimilarity. A few residues highlighted in grey are conserved between the 1210 and 1450 anti-
gen binding. The importance of residue H.Y58 in 1450 binding was confirmed by site directed
mutagenesis and loss of binding of the antibody carrying H.A58 (Figure 23C). The data indicates
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that VH3-23/Vκ1-5/KCDR3:8 and VH3-33/Vκ1-5/KCDR3:8 antibodies share similar overall bind-
ing mode, but nevertheless differ in the exact set of antigen-antibody interactions. A sandwich
binding mode of VH3-23/Vκ1-5/KCDR3:8 antibodies thus seems to be very likely.
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Figure 23. Structure model of a representative VH3-23/Vκ1-5/KCDR3:8 antibody sug-
gest binding mode similar to VH3-33/Vκ1-5/KCDR3:8 antibodies. A: Computational mod-
els of antibodies 1450 and 1210 bound to NANP5 compared to the crystalstructure of 1210 bound
to NANP5. KCDR1, KCDR2, KCDR3 are shown in light green, green and dark green, respectively.
HCDR1, HCDR2 and HCDR3 are colored in light teal, teal and dark teal, respectively. Residues at
positions H.56 and K.93 are shown in red. NANP5 residues are shown as stick representation. B:
Residues involved in antigen binding in the 1210-NANP5 crystal structure, and in the 1210-NANP5
and 1450-NANP5 models determined using PDBePISA [53]. C: Pf CSP ELISA reactivity of antibody
1450 and alanine mutant 1450 H.Y58 A.
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9 Discussion
9.1 SciReptor as a tool for annotation of adaptive immune receptor reper-
toires on single-cell level
An essential step in this work was to adapt the existing Ig sequencing protocol to the Illumina
sequencing technology and to develop a bioinformatics pipeline that would make it easy to access
the sequence annotation. The sciReptor software was developed and successfully used to analyse
the raw sequencing data for all B cell repertoires presented in this work. The efficiency of suc-
cessful computational sequence annotation was comparable to the efficiencies estimated by Sanger
sequencing [68]. After its first publication sciReptor has further been developed to analyse T cell
repertoires (Bartsch and Busse, unpublished work).
Recent developments in the field of immune receptor sequencing have highlighted the importance of
correct genomic databases for accurate annotation of germline genes and somatic hypermutations.
Several new computational tools allow de novo allele prediction based on repertoire data sets [22, 37].
However, in the case of the here studied datasets, sequence and cell numbers are not high enough
to reliably reconstruct germline gene sequences. If germline gene reconstruction prior to repertoire
annotation was to become relevant, bulk sequencing could be applied to generate a database of
germline genes which could then be plugged in into the library module of sciReptor.
In contrary to the widely used bulk sequencing approaches, sequencing of B cell repertoires at single-
cell level allows correct assessment of clonality as well as identification of paired heavy and light
chain genes. Especially the latter is essential when exploring public antibody repertoires. In the
field of adaptive immune receptor repertoire (AIRR) sequencing sciReptor remains one of the few
tool designed to analyse repertoires at single-cell level, and capable of integrating non-sequence
annotation like cellular phenotypes for example. Other common AIRR analysis tools have integrated
consensus building functions [37, 107], but none of them allows full integration of annotations at
single-cell level. An additional major challenge in the assessment of antibody repertoires remains the
lack of high-throughput expression systems that would allow systematic testing of antibody reactivity.
The here presented work highlights the necessity of testing antibody reactivities, especially when
investigating public repertoires. First attempts on high-throughput affinity measurements have been
made [2], but they are by far not commonly usable.
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9.2 Pre-erythrocytic immune response response in LaCHMI donors
An important heterogeneity of pre-erythrocytic immune responses was observed in the Gabonese
donors during the course of the LaCHMI study. Not only was the study outcome in terms of
disease and symptom development very different from donor to donor, but also the humoral immune
parameters differed a lot.
9.2.1 Heterogeneity of the study outcome is due to heterogeneity of pre-erythrocytic
immunity
Out of the 8 Gabonese LaCHMI subjects that were completely protected against the infection, only
3 showed relevant anti-Pf CSP titers before the start of the study on day C-1. The malaria history
of the Gabonese subjects recruited into the LaCHMI trial is difficult to judge and thus it is not clear
whether the low frequency of pre-existing pre-erythrocytic immunity and the even lower frequency
of Pf CSP serum antibodies is due to lack of sufficient previous exposure or due to heterogeneity of
the immune responses upon repeated exposure. However low frequencies of anti-Pf CSP responses
in naturally exposed individuals have been described in the endemic areas, including the region the
LaCHMI study participant were living in [46, 104]. According to a study, that compared rates of
seroconversion for different antigens over 10 years, the reduced frequencies of anti-Pf CSP serum
antibody titers may be due to lower exposure frequencies [116].
Interestingly, the donors that have an active immune response and increase the levels of anti-Pf CSP
titers in serum from day C-1 to day D28 are the ones that are also treated early on in the infection. It
has been reported that the development of blood stage parasites and acute malaria is detrimental for
the successful development of pre-erythrocytic humoral immunity [50]. This hypothesis could explain
the lack of anti-Pf CSP titers in donors that develop asymptomatic parasitemia and also present a
mechanism of why under natural exposure only few individuals mount anti-Pf CSP memory B cell
responses. However, this hypothesis does not give sufficient explanation for why the protected
donors that eliminate the parasite before blood stage parasitemia do not raise anti-Pf CSP titers.
The cases of pre-erythrocytic immunity without presence of anti-Pf CSP serum titers confirm results
from previous studies in naive donors [70] and illustrate the presence of other non antibody dependent
and non Pf CSP dependent mechanisms for immunity against sporozoite infection. The presence
of a strong plasmablast response without raising levels of anti-Pf CSP titers, as observed in donors
L1-002 or L1-009, highlights that the humoral immune response can also be directed against other
parasite antigens. Non humoral mechanisms of pre-erythrocytic immunity include CD8 T cells or
interferon-gamma secreting CD4 T cells that act against the Pf liver stages or EEFs [64, 94, 95].
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9.2.2 Failure of identification of Pf CSP reactive antibodies in LaCHMI participants
Several cloning attempts failed to identify antibodies with measurable Pf CSP reactivity in ELISA
in the LaCHMI cohort, although the donors L1-011, L1-021 and L1-022 were selected for repertoire
analysis based on their humoral anti-Pf CSP profile. The results correspond well to the observations
of a previous study in Pf experienced donors, where the frequencies of Pf CSP reactive B cells were
also extremely low [104].
The selection of Gabonese donors for repertoire sequencing was based on the assumption that anti-
Pf CSP titers also correlate with circulating Pf CSP specific memory B cells. The failure to isolate
Pf CSP reactive antibodies from the sorted cells however could be due to the fact that only very
few B cells with measurable affinity were circulating in the peripheral blood of the selected donors
at the time of blood sampling. The screening approaches then failed to identify them because they
were too rare. Indeed, the three donors selected for repertoire analysis did not show an increase of
anti-Pf CSP serum titers, but rather even tended to decrease them, which suggests that there was
no active anti-Pf CSP B cell response after sporozoite injection. It is possible that the donors had
few reactive memory B cells in the circulating blood and that the serum titers were maintained by
plasma cells residing in the bone marrow for example. Pf CSP exposure under natural conditions
is with much lower antigen quantities than the repeated immunization during the TuCHMI study
e.g. and thus the memory responses cannot be compared. Retrospectively, in order to find higher
numbers of circulating Pf CSP specific B cells it would probably have been better to choose the
donors with active ongoing anti-Pf CSP B cell response, i.e. with increasing anti-Pf CSP titers
during the infection.
Even if the previous hypothesis is reasonable, there are several indications for an Pf CSP specific
population within the B cell memory of the selected donors. First of all, the enrichment of Pf CSP
reactive B cells in FACS to a level of 2% (Figure 6) compared to a baseline level of approximately
0.02 % in healthy donors [104] indicates the presence of a truly Pf CSP specific population. In
addition, AtM B cells were found to be enriched in the Pf CSP binding B cell population and showed
a phenotype similar to the one previously described for AtM. This observation indicates that the
Pf CSP binding of cells in FACS is not an artefact but that Pf CSP-specific B cells are present in the
AtM population. This population has indeed previously been described to be reactive to pathogen
antigens [23, 66].
The lack of identification of Pf CSP specific B cells is thus more likely do to a lack of sensitivity of
the reactivity assessment. Antibodies with a very low Pf CSP affinity, may still bind Pf CSP in FACS,
but the interaction may not be detectable any more in the less sensitive ELISA method. Supporting
this idea, many of the BCRs that bound Pf CSP in FACS had an IgM isotype, a phenomenon that has
also been observed in the anti-Pf CSP repertoire of European CHMI donors [69], but not in antibody
repertoires directed against viral antigens for example [51]. However the antibody reactivity was
tested on antibodies cloned and expressed as IgG1 isotypes, which in contrast to the pentameric IgM
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only has two antigen binding sites and may thus be less useful to detect antigen binding in which
avidity plays a major role. In addition, selection of antibodies with low affinity to Pf CSP could be
favoured by the repetitive structure of the protein or by anti-idiotope interactions that select BCRs
that only have weak affinity to the antigen epitope but higher affinity in the complex assembly. In
other words, anti-idiotope interactions could lower the threshold of antibody-antigen binding affinity
that is necessary to activate a specific B cell.
In summary, the LaCHMI participants showed very heterogeneous pre-erythrocytic immune re-
sponses, especially to the major sporozoite antigen Pf CSP. Moreover, under natural exposure condi-
tions, it seems not only to be difficult to mount an anti-Pf CSP response at all, but it also seems to
be difficult to recruit highly reactive antibodies against Pf CSP. The present work suggests that many
B cells with low affinity are recruited, which may be due to the repetitive structure of the Pf CSP
antigen in combination with interactions between antibodies binding to neighbouring epitopes.
9.3 Technical consideration on public antibody repertoires and the im-
pact of sequence similarity
A sequence similarity clustering approach was used to identify the public B cell repertoire after
CHMI, i.e. B cells encoding antibodies with similar sequence and supposedly also similar specificity.
The approach led to an identification of a set of small and very diverse clusters of public antibodies
encoded by very different heavy and light variable gene combinations. Focussing on anti-Pf CSP an-
tibodies, the relationships between sequence, structure and antigen binding were further investigated
to describe the characteristics of the public anti-Pf CSP repertoire.
9.3.1 Predicting antibody binding based on sequence similarity should be confirmed by
reactivity testing
The predictive clustering approach presented in Figure 11 demonstrates that sequence similarity
usually also correlates with similar reactivity. However, only the reactive antibodies from European
donors were successfully clustered using this approach. For the African donors, only few antibodies
clustered and none of the antibodies that were cloned also actually bound Pf CSP in ELISA. Overall,
the clustering approach seems to be sensitive and specific enough when clustering repertoires that
contain the desired antibodies at sufficient frequency. For the Gabonese repertoires, the frequency
of Pf CSP specific B cells was too low and thus too many false positive antibodies were identified.
It can be overall concluded that basing the definition of public repertoire only on sequence similarity
is difficult and should not be done without confirming the reactivity of the antibodies. Although
most of the public repertoire studies rely on sequence data only, recent studies start to include small
scale reactivity data, which is still limited by the lack of high-throughput expression systems [44].
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9.3.2 The accuracy of public repertoire identification is influenced by the choice of the
clustering algorithm
The technical implementation of antibody clustering in this work had specific problems related to
the processes which lead to the generation of an immunoglobulin sequence. In the here presented
approach the complete antibody sequence starting from CDR1 to the end of the J segment was
aligned, giving high importance to the long germline encoded variable gene and less importance
to the shorter but highly diverse CDR3 regions generated by recombination. Antibodies with low
levels of somatic hypermutations eventually clustered together although they had very little HCDR3
similarity and not the same reactivity. This was probably the case for the antibody with VH3-
33/Vκ1-5/KCDR3:8 sequence characteristics that was identified in one of the Gabonese donors but
did not bind even when the critical mutations were reverted. Recognition of different antigens that is
only based on HCDR3 differences has indeed also been described in detail in a previous study [102].
In addition to specificity problems, the approach is also not well suited to identify antibodies with
similar antigen binding sites but high levels of somatic hypermutation, since replacements at positions
irrelevant for antigen binding diversify the antibody sequence.
The results obtained using a simple full length amino acid sequence alignment were satisfying, but
could however be improved by enhancing the clustering algorithm. Similar binding relies mostly on
single residues that are exposed to the antibody surface and even though the antibody framework
can be quite different, these residues can still be exposed to the surface in a similar configuration. To
take into account this knowledge, it would be useful to combine structure modelling and alignment
with sequence alignment.
9.3.3 Sequence similarity only partly entails structure similarity
In addition to reactivity assessment of public anti-Pf CSP antibodies, structure modelling was used
to assess the structural diversity within two sets of antibodies with high sequence similarity. The
HCDR3 is the antibody loop with the highest sequence and structure variation and it is thus also
the one that is most extensively modified during the homology modelling in the Rosetta software
package. Models with high similarity to the actual protein structure are usually identified by structural
convergence within the models with the best scores. In this work, antibodies utilizing IGLV1-47
showed convergent structure clustering, whereas VH3-33/Vκ1-5/KCDR3:8 antibody models did not
indicate any structural convergence.
It can be concluded, that HCDR3 in the IGLV1-47 utilizing antibodies have a similar conformations
which might also be due to a shorter length and due to the presence of a proline residue within
the HCDR3 region. Shorter HCDR3 loops are less flexible and proline residues are known to rigidify
protein loops. The HCDR3 of VH3-33/Vκ1-5/KCDR3:8 antibodies might simply be less rigid and
play a minor role in the interactions with the NANP-repeat. The minor contribution of HCDR3
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in antigen binding of VH3-33/Vκ1-5/KCDR3:8 was also confirmed by crystallization experiments
conducted by J.-P. Julien. The current literature concerning the structure evolution of antibodies
during the course of affinity maturation reports structure convergence that goes along with sequence
convergence [92]. However affinity maturation does not typically result in rigidification of antibody
structures [49], which supports the idea of high affinity being mediated even with flexible HCDR3
regions.
The literature as well as the here presented data on molecular characterization of binding interactions
indicates many different ways in how binding can be accomplished, ranging from isolated binding
motifs to complex interaction networks of antibody and antigen. As discussed above, it is difficult
to find an adequate clustering algorithm for public antibodies, and resulting hypothesis should be
confirmed by reactivity testing. Sequence similarity does not always reflect structure similarity,
and, most importantly, similar binding can be achieved even with small differences in structure, as
demonstrated by the data on VH3-33/Vκ1-5/KCDR3:8 antibodies.
9.4 Characteristics of the common anti-Pf CSP B cell repertoire after
CHMI
Based on the observations from the predictive cloning of anti-Pf CSP specific antibodies, the clusters
of public antibodies identified in the European CHMI donors also share similar reactivity. The
common anti-Pf sporozoite repertoire is surprisingly heterogeneous and is composed by several small
and diverse clusters of similarity. In contrary to that, independent studies on B cell repertoires after
influenza vaccinations have reported stronger convergence within antibody rearrangements and more
homogeneous antibody response between donors [48, 110]. One explanation for this phenomenon is
certainly that immunization with a complete parasite confronts the immune system with a diverse
set of antigenic stimuli and that B cells with many different specificities are activated.
However, also the subset of the public repertoire specific to Pf CSP seems to be rather diverse.
The induction of a broad and diverse response of antibodies could be due to the high abundance
of antigen during the immunization combined with a low frequency of Pf CSP specific mature naive
B cells. The public antibodies with high affinity to the NANP-repeat have sequence characteristics
that likely make them rare in generation of the repertoire (KCDR3 length of 8 amino acids, IGHV
gene restriction e.g.). Antibody targets in other diseases may be easier to bind or be able to activate
a higher number of corresponding specific mature naive B cells. The influence of mature naive B cell
precursor frequency on the development of the memory B cell repertoire to a specific antigen has
recently been illustrated in a mouse system with a VRCO1-class germline targeting HIV antigen [1].
69
9.4.1 IGHV3 prevalence within public anti-Pf CSP antibodies
It appears that clusters of common anti-Pf CSP antibodies frequently utilize IgH genes from the
IGHV3 family, a claim that was already made when looking at the complete anti-Pf CSP reper-
toire [69]. In the same lines, a study on RTS,S induced antibodies [75] as well as a study on naturally
induced anti-Pf CSP antibodies [104] also identified antibodies utilizing IGHV3 genes. A preferred
usage of IGHV3 heavy variable genes was equally described for bacterial polysaccharides [3], whereas
hemagglutinin of influenza frequently is bound by antibodies encoded by the IGHV1 [7, 48, 110] and
antibodies in celiac disease often utilize IGHV5-51 [88].
The IGHV family preferentially found in antibodies against a certain target is most likely influenced
by the structure complementarity of the resulting antibody with the antigen. The resolved crystal
structures of antibodies binding to NANP-repeat peptides show binding of the peptide in a concave
pocket, that is formed by several CDRs of the antibody ([75, 104], crystal structure provided by
J.P. Julien). The here presented data on molecular characteristics of public anti-Pf CSP antibodies
confirms, that several regions of the antibody are important for antigen binding. In contrast to this,
in antibodies binding the receptor binding site of influenza hemagglutinin for example single motifs
within the HCDR3 interact with the antigen [93, 124]. Several very different germline genes can
encode these antibodies. Similar observations were made for antibodies binding the HIV envelope
V2 Apex, where antigen binding is mediated by a motif in the HCDR3 [6].
Interestingly, it has been reported that concavity of the paratope as for example determined by CDR
lengths influences the target preference between globular and disordered antigens [21, 59]. The
different IGHV genes are known to have different intrinsic lengths of CDR region, which can adopt
different conformations according to their amino acid conformation. A new clustering approach gives
good overview over the different loop configurations found in antibody CDRs [71]. According to
this clustering, interestingly IGHV3-33, IGHV3-23 and IGHV4-59 have similar CDR conformations,
which are also the genes enriched in the public repertoire (Figure 10).
9.4.2 The public anti-Pf CSP repertoire is influenced by genetic polymorphisms
In addition to the specificity and binding, the diversity and similarity of public antibody repertoires
can also be determined by the immunoglobulin genes present in the germline of every individual.
The here described VH3-33/Vκ1-5/KCDR3:8 antibodies depend on a IGHV germline gene that
is absent in some individuals. A previous study on complete IGHV haplotype sequences reported
that IGHV3-33 is located in a locus of major structural polymorphism within the human IGHV
locus [114, 115]. Genomic or allelic predisposition to mount a certain type of antibodies has also
been discussed for antibodies in different viral infections [7, 58, 127]. Other genetic polymorphisms
that lead to differences in B cell repertoire generation could be copy number variations of specific
germline genes [7] or polymorphisms in regulatory regions of the immunoglobulin loci.
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Nevertheless, genetic predispositions only explain part of the variability that is observed in antibody
repertoires. A twin study on acute responses to Varicella-Zoster virus vaccination reported that twins
share similarities in the overall memory B cell compartment, but that stochastic effects dominate
the selection of clones in acute immune responses [111]. In the case of hepatitis B vaccination, a
well-known example for incomplete humoral immune responses in a certain number of patients, it
has been hypothesised that HLA restriction might play a role [113] or that the ratio of Th1- and
Th2-type T cells plays a role in the generation of the B cell response [25].
In summary, the present work highlights two possible explanations for the observed heterogeneity of
the common anti-Pf CSP repertoire: low precursor frequencies of Pf CSP-specific B cells and genetic
polymorphisms. The apparent enrichment of a specific IGHV family may be due to the conformation
and length of germline encoded CDRs.
9.5 Antigen binding and affinity maturation against a repetitive epitope
The most surprising and interesting result of the present work is the observation that antibodies
directed against Pf CSP directly interact with each other. The interaction of the two antibody
molecules, as determined in the crystal structure by J.P. Julien, is absolutely symmetrical in terms
of antigen binding, which means that the interactions between antibody and antigen are identical
in both Fabs contributing to the sandwich. Direct interactions of antibodies with themselves at the
antigen binding site have previously been observed in two cases. In 1996 an anti-idiotype antibody
was described, that forms dimers, but without the simultaneous involvement of antigen binding [8].
In 2016, another histone-specific antibody was reported to bind its antigen in a sandwich conforma-
tion, but the antigen interaction with ”upper” and ”lower” sandwich Fab are non-symmetric [39].
The symmetry of the here described anti-Pf CSP antibody binding is only possible due to the repet-
itive sequence and structure of the NANP-repeat peptide.
9.5.1 Antigen binding conformation leads to anti-idiotope affinity maturation
The selection patterns of anti-idiotope affinity maturation are one of the observations that indicated
a common Pf CSP binding mode that involves direct interaction of neighbouring antibodies. Ca.
50% of the affinity maturation observed in VH3-33/Vκ1-5/KCDR3:8 antibodies is directed against
the antibody paratope of a neighbouring antibody and thus improves the assembly of an antigen
with several antibodies. In VH3-23/Vκ1-5/KCDR3:8 antibodies, this percentage might even be
higher since no other hotspots of affinity maturation become apparent in the sequence alignments.
This type of self-dependent affinity maturation of BCRs has not been described before. Although
there exist reports on autonomous signalling in CLL B cells, where BCRs directly interact with each
other and affinity mature against them-self [61], this phenomenon has never been associated with
improved binding to antigens.
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9.5.2 Potential biological mechanisms for anti-idiotope affinity maturation
Mechanistically the anti-idiotope affinity maturation could rely on two different processes: antibody
feedback of antibodies binding to Pf CSP antigen in germinal centres or direct improvement BCRs
cross-linking on the surface of a B cell. Antibody feedback has been primarily reported to mask
epitopes on antigens and thus restrict the set of available BCR targets in germinal center reac-
tions [99, 132]. However it is also possible that antibodies binding to antigen in germinal centers
might extend the epitopes targeted by newly generated B cells and antibodies, as in anti-idiotope
affinity maturation. Anti-idiotope affinity maturation due to direct improvement of BCR cross-
linking on the B cell surface is also conceivable, although it would have to be clearly shown that
this is sterically possible. In order to investigate the two hypothesis, experiments could be done to
measure the capacity of different antibody mutants (with or without anti-idiotope mutations) to
activate B cells in vitro, as e.g. calcium flux experiments.
While the antigen binding of the two Fabs presented in the crystal structure is symmetric, the inter-
action between the two antibody variable regions is asymmetric (data not shown, crytal structure
kindly provided by J.-P. Julien). Especially in the case of interaction between BCRs from the same
cell, this aspect could induce competition of different mutations and lead to inefficient affinity mat-
uration over a longer period of time. In order to further investigate this, experiments in genetically
modified mice, that only express one BCR of VH3-33/Vκ1-5/KCDR3:8-type, could be performed.
The evolution of the BCR sequences could be monitored throughout multiple immunizations with
Pf CSP.
9.5.3 Role of the repetitive Pf CSP structure in antibody binding
The NANP-repeat structure of Pf CSP is essential to enable the direct interaction of two antigen
binding sites. Especially the type-I and type-II β turns that are facilitated by the proline residues
and that alternate to form a loop structure are essential to bring two antibody molecules into close
proximity. None of the other Plasmodium species has the exact same repetitive pattern, but the CSP
protein of Plasmodium berghei e.g. uses several repetitive motifs that include proline but not the N
and A amino acids that form stabilizing hydrogen bonds in the Pf CSP repeat. It is thus unlikely that
antibodies directed against the CSP of other Plasmodium species form the same type of complex.
Nevertheless also binding to the repetitive molecule at other angles could induce direct interactions
of antibodies. Similar to that, other repetitive antigens like polysaccharides or viral capsule proteins
could induce non-antigen directed affinity maturation by allowing interactions between antibodies or
BCRs binding neighbouring epitopes.
In summary, the observations on anti-idiotope interaction and affinity maturation of antiPf CSP
antibodies highlight the importance of the repetitive structure of the NANP-repeat in immune
responses against the parasite. It is important to note, that the here presented results broaden the
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understanding of antibody binding to Pf CSP. It was previously postulated that binding of antibodies
to Pf CSP might have considerable entropic cost due to the flexible structure of Pf CSP and necessary
stabilization of the antigen [26]. However, the principle of anti-idiotope affinity maturation shows
that the complex assembly of several antibodies to the antigen might actually be beneficial and
increase antibody avidity by cooperative effects.
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10 Outlook
The discovery of anti-idiotope binding and affinity maturation of antibodies binding to the repeat
domain of Pf CSP raises several novel questions that will have to be addressed in future research.
First, it will be important for the immunological community to investigate whether this type of
complex assembly also plays a role in other repetitive antigens like bacterial polysaccharides. In this
context it will be necessary to understand whether anti-idiotope binding can induce or facilitate T
cell independent responses.
Second, it will be crucial to delimit the exact effect of such interactions on in vivo immune reactions
in order to find out whether the interaction is used by the parasite as a kind of immune evasion
mechanism or whether it simply makes the B cell response to the antigen more efficient. The
parasite could for example use the repetitive region of Pf CSP to induce anti-idiotope interactions in
antibodies and reduce the affinity threshold of B cells that it activates. To test this, B cell activation
experiments with BCRs identified in the Gabonese donors could be performed to test whether these
BCRs are at all activated by Pf CSP. In line with the theory of parasite immune evasion, preliminary
results on parasite inhibition in vitro and in vivo indicate that anti-idiotope binding does not play a
role in parasite neutralization. Sterical hindrance due to high Pf CSP density on the parasite surface
could for example impair efficient anti-idiotope interactions on the parasite surface. All affinity
maturation that increases anti-idiotope affinity would then have no effect on parasite inhibition.
With the idea of exploiting anti-idiotope binding to target specific germline recombinations in vac-
cination, we have recently filed a patent for a chimeric complex of a VH3-33/Vκ1-5/KCDR3:8 Fab
covalently linked to a NANP5 repeat. This construct might be used to specifically target the germline
precursor B cells that lead to high-affine and protective antibodies against malaria. However, since it
was shown in this work, that structural polymorphisms of the IGHV locus might influence the gener-
ation of antiPf CSP antibodies, this approach has to be investigated thoroughly. In case the chimeric
complex could only target VH3-33/Vκ1-5/KCDR3:8 B cells specifically, only such individuals with
IGHV3-33 in their germline DNA would benefit from the vaccination.
Finally, in the same lines, it would be interesting to investigate the population genetics of IGHV3-33
deletions. Since this gene is used in high-affine germline-like anti-sporozoite antibodies, having the
gene could have an advantage for malaria survival. The current human genome databases however
do not allow clear statements about IGHV3-33 frequencies in European and Africans for example,
because the annotations are not yet precise enough to differentiate between the different very similar
germline genes.
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13 Appendix
13.1 FACS analysis during LaCHMI trial
Figure 24. Gating strategy for measurement of frequencies of three B cell sub-populations: plas-
mablast (PB), atypical memory B cells (AtM) and classical memory B cells (CM).
85
13.1.1 B cell population frequencies in the different LaCHMI participants
The following panels depict the frequencies of classical memory B cells (CM), atypical memory B
cells (AtM) and plasmablasts (PB) within the complete CD19+ B cell population. The donors are
classified according to their background (European, Gabonese) and according to whether developed
blood stage parasitemia or not. Grey vertical lines indicate timepoints at which 20 mL of blood were
sampled and PBMCs cryo-preserved.
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Gabonese LaCHMI donors with parasitemia
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Gabonese LaCHMI donors without parasitemia
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13.2 1210 and 2163 mutants
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13.3 Primer sequences
13.3.1 PCR primers for generation of primary amplicons
First PCR forward primers
hIGHV-1/7-066-fw ACAGGTGCCCACTCCCAGGTGCAG
hIGHV-1/7-017-fw ATGGACTGGACCTGGAG
hIGHV-1/7-041-fw TCCTCTTTGTGGTGGCAGCAGC
hIGHV-2-035-fw TCCACGCTCCTGCTRCTGAC
hIGHV-3-066-fw AAGGTGTCCAGTGTGARGTGCAG
hIGHV-3-057-fw TAAAAGGTGTCCAGTGT
hIGHV-4/6-066-fw CCCAGATGGGTCCTGTCCCAGGTGCAG
hIGHV-4-022-fw ATGAAACACCTGTGGTTCTTCC
hIGHV-5-066-fw CAAGGAGTCTGTTCCGAGGTGCAG
hIGKV-1-060-fw ATGAGGSTCCCYGCTCAGCTGCTGG
hIGKV-3-049-fw CTCTTCCTCCTGCTACTCTGGCTCCCAG
hIGKV-4-049-fw ATTTCTCTGTTGCTCTGGATCTCTG
hIGLV-1-068-fw GGTCCTGGGCCCAGTCTGTGCTG
hIGLV-2-068-fw GGTCCTGGGCCCAGTCTGCCCTG
hIGLV-3-068-fw GCTCTGTGACCTCCTATGAGCTG
hIGLV-4/5-068-fw GGTCTCTCTCSCAGCYTGTGCTG
hIGLV-6-068-fw GTTCTTGGGCCAATTTTATGCTG
hIGLV-7-068-fw GGTCCAATTCYCAGGCTGTGGTG
hIGLV-8-083-fw GAGTGGATTCTCAGACTGTGGTG
First PCR reverse primers
hIGHA-111-rv GTCCGCTTTCGCTCCAGGTCACACT
hIGHE-140-rv AAGGTCATAGTTGTCCCGTTGAGG
hIGHG-137-rv GGAAGGTGTGCACGCCGCTGGTC
hIGHM-082-rv GGAAGGAAGTCCTGTGCGAGGC
hIGKC-172-rv GTGCTGTCCTTGCTGTCCTGCT
hIGLC-057-rv CACCAGTGTGGCCTTGTTGGCTTG
Second PCR forward primers
hIGHV-pan-080-fw AGGTGCAGCTGCTGGAGTCKGG
hIGKV-pan-fw ATGACCCAGWCTCCABYCWCCCTG
hIGLV-pa1-fw CAGYCTGYSCTGACTCA
hIGLV-pa2-fw TCCTATGAGCTGACWCAG
90
Second PCR reverse primers
hIGHA-076-rv GGAAGAAGCCCTGGACCAGGC
hIGHE-070-rv CCAGGCAGCCCAGAGTCACGG
hIGHG-074-rv AGTCCTTGACCAGGCAGCCC
hIGHM-031-rv GGGAATTCTCACAGGAGACGA
hIGKC-032-rv AACTGCTCATCAGATGGCGGG
hIGLC-026-rv TCAGAGGAGGGYGGGAACAGAGTG
13.3.2 Primers for specific PCR and subsequent cloning
Specific primers for heavy chain
5’ AgeI VH1 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGGTGCAG
5’ AgeI VH1-18 CTGCAACCGGTGTACATTCCCAGGTTCAGCTGGTGCAG
5’ AgeI VH1-24 CTGCAACCGGTGTACATTCCCAGGTCCAGCTGGTACAG
5’ AgeI VH1/5 CTGCAACCGGTGTACATTCCGAGGTGCAGCTGGTGCAG
5’ AgeI VH3 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGGTGGAG
5’ AgeI VH3-9 CTGCAACCGGTGTACATTCTGAAGTGCAGCTGGTGGAG
5’ AgeI VH3-23 CTGCAACCGGTGTACATTCTGAGGTGCAGCTGTTGGAG
5’ AgeI VH3-33 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGGAG
5’ AgeI VH4 CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGGAG
5’ AgeI VH4-34 CTGCAACCGGTGTACATTCCCAGGTGCAGCTACAGCAGTG
5’ AgeI VH4-39 CTGCAACCGGTGTACATTCCCAGCTGCAGCTGCAGGAG
5’ AgeI VH6-1 CTGCAACCGGTGTACATTCCCAGGTACAGCTGCAGCAG
5’ AgeI VH7 CTGCAACCGGTGTACATTCTCAGGTGCAGCTGGTGCAATCTGG
3’ SalI JH1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG
3’ SalI JH3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG
3’ SalI JH6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG
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Specific primers for kappa chain
5’ AgeI Vk1-5 CTGCAACCGGTGTACATTCTGACATCCAGATGACCCAGTC
5’ AgeI Vk1-5 TTGTGCTGCAACCGGTGTACATTCAGACATCCAGTTGACCCAGTCT
5’ AgeI Vk1-6 CTGCAACCGGTGTACATTCTGCCATCCAGATGACCCAGTC
5’ AgeI Vk1-13 CTGCAACCGGTGTACATTCTGCCATCCAGTTGACCCAGTC
5’ AgeI Vk1D-43 CTGCAACCGGTGTACATTGTGCCATCCGGATGACCCAGTC
5’ AgeI Vk2-24 CTGCAACCGGTGTACATGGGGATATTGTGATGACCCAGAC
5’ AgeI Vk2-28 CTGCAACCGGTGTACATGGGGATATTGTGATGACTCAGTC
5’ AgeI Vk2-30 CTGCAACCGGTGTACATGGGGATGTTGTGATGACTCAGTC
5’ AgeI Vk3-11 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACACAGTC
5’ AgeI Vk3-15 CTGCAACCGGTGTACATTCAGAAATAGTGATGACGCAGTC
5’ AgeI Vk3-20 TTGTGCTGCAACCGGTGTACATTCAGAAATTGTGTTGACGCAGTCT
5’ AgeI Vk4-1 CTGCAACCGGTGTACATTCGGACATCGTGATGACCCAGTC
3’ BsiWI Jk1/4 GCCACCGTACGTTTGATYTCCACCTTGGTC
3’ BsiWI Jk2 GCCACCGTACGTTTGATCTCCAGCTTGGTC
3’ BsiWI Jk3 GCCACCGTACGTTTGATATCCACTTTGGTC
3’ BsiWI Jk5 GCCACCGTACGTTTAATCTCCAGTCGTGTC
Specific primers for lambda chain
5’ AgeI Vl1 CTGCTACCGGTTCCTGGGCCCAGTCTGTGCTGACKCAG
5’ AgeI Vl2 CTGCTACCGGTTCCTGGGCCCAGTCTGCCCTGACTCAG
5’ AgeI Vl3 CTGCTACCGGTTCTGTGACCTCCTATGAGCTGACWCAG
5’ AgeI Vl4/5 CTGCTACCGGTTCTCTCTCSCAGCYTGTGCTGACTCA
5’ AgeI Vl6 CTGCTACCGGTTCTTGGGCCAATTTTATGCTGACTCAG
5’ AgeI Vl7/8 CTGCTACCGGTTCCAATTCYCAGRCTGTGGTGACYCAG
hCl-040-XhoI CTCCTCACTCGAGGGYGGGAACAGAGTG
13.3.3 Primers for insert check
hIGHG-084-Rv GTTCGGGGAAGTAGTCCTTGAC
hIGKC-172-Rv GTGCTGTCCTTGCTGTCCTGCT
hIGLC-057-Rv CACCAGTGTGGCCTTGTTGGCTTG
Absense GCTTCGTTAGAACGCGGCTAC
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13.3.4 Primers for IGHV genotyping
IGHV3-30 079 Fw 01 ACAGGTAGTCCACACACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 02 ACCAACACCACAGTCACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 03 ACCTGATCTCGAACCTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 04 ACGAGTAGTCTGGAGTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 05 ACGAGTTGACCATCCTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 06 ACGTACAGCACTACCTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 07 ACGTACTCAGACAGTCCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 08 ACGTAGAGGAGACTCACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 09 ACGTAGTCCTCTCTGTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 10 ACTCGATCCAGTTGTCCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 11 ACTCGTAGCTGTGAACCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 12 ACTCGTCTACTGTGTCCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 13 ACTGAGACGAACACGACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 14 AGAGCTACCAGTTCACCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 15 AGAGCTCAAGTGGTTCCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 16 AGGACAGTAGTGGTCACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 17 AGGTTCACTGAGAGGACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 18 AGGTTCCAGACTCACACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 19 AGTCCTCTGTCAAGGTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 20 AGTCCTGTTCTCTGGACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 21 AGTCCTTCGATCTCCTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 22 AGTGTCACCTTCGAGACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 23 CAACGTCTTGAGAGTGCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 24 CAAGAGGACAGTTCTGCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 25 CACTACAGGTGTTCCACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 26 TGTCAGGACTTGGAGTCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 27 TGTGGACTAGAGGTAGCAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 079 Fw 28 TGTGGTAGACACGAGACAGGTGCAGCTGGTGGAGTCTGGGG
IGHV3-30 348 Rv TCTCTCGCACAGTAATACACAGCCGTGTCC
3’ SalI JH1/2/4/5 TGCGAAGTCGACGCTGAGGAGACGGTGACCAG
3’ SalI JH3 TGCGAAGTCGACGCTGAAGAGACGGTGACCATTG
3’ SalI JH6 TGCGAAGTCGACGCTGAGGAGACGGTGACCGTG
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13.3.5 Primers for site directed mutagenesis
Mutant Forward primer Reverse primer
D07g1x1349 T84A CATCCTGAGAgccGAGGACACGG TTCATTTGCAGATACAGTGAGTTCTTG
D07xxl1349 N31K CATCGGAAGTaagTATCTATACTGG TTGGAGCTGCTTCCAGAAC
D07g1x1349 Y58A GTGGGTTTCAgccATTAGTAGTAGTAGTAGTACCATATACTAC TCCAGCCCCTTCCCTGGA
D07xxl1349 Y34A TAATTATCTAgccTGGTACCAGCAGC CTTCCGATGTTGGAGCTG
D0972h2219 W52R GGCAGTTATAaggTATGATGGAAGTAAAAAATACTATG ACCCACTCCAGCCCCTTG
D0972h2219 Y53A AGTTATATGGgctGATGGAAGTAAAAAATACTATGCAGACTCCGTGAAG GCCACCCACTCCAGCCCC
D0972k2219 K50E CCTGATCTATgagGCGTCTCGTTTAG AGCTTAGGGGCTTTCCCT
D0972k2219 W35A TATTAGTAGCgcgTTGGCCTGGTATCAGCAG CTCTGACTGGCCCGGCAA
D0972h2140 W52A GGCAATTATAgcgTATGATGGAAGTAAGAAATACTATGCAGAC ACCCACTCCAGCCCCTTG
D0972h2140 W52R GGCAATTATAaggTATGATGGAAGTAAGAAATACTATG ACCCACTCCAGCCCCTTG
D0972h2140 W52S GGCAATTATAagcTATGATGGAAGTAAGAAATACTATGCAG ACCCACTCCAGCCCCTTG
D0972h2140 Y59A AAGTAAGAAAgccTATGCAGACTCCG CCATCATACCATATAATTGCC
D0972k2140 F97Y GTATAAGAGTtacTGGACGTTCG TGTTGGCAGTAATAAGTTG
D0972k2140 W35A TATTAGTAGCgcgTTGGCCTGGTATCAGCAG CTCTGACTGGCCCGGCAA
D0972h2290 W52R GGCAGTTATAaggTATGATGGAAGTAATAAATACTATG ACCCACTCCAGCCCCTTG
D0972h2290 W52S GGCAGTTATAtcgTATGATGGAAGTAATAAATACTATG ACCCACTCCAGCCCCTTG
D0972h2290 N57K TGATGGAAGTaagAAATACTATGC TACCATATAACTGCCACC
D0972h2290 V50I GTGGGTGGCAattATATGGTATGATGG TCCAGCCCCTTGCCTGGA
D0773h1239 R52W AGGTTTCATTtggAGCAAAGCTTATGGTGG ACCCACTCCAGCCCCTTC
D0972h2163 W52S GGCAGTTATAtcgTATGATGGAAGTAATAAATACTATG ACCCACTCCAGCCCCTTG
D0773h1210 W52A GGCAGTTATAaggTATGATGGAAGTAAGAAATAC ACCCACTCCAGCCCCTTG
D0773h1210 K57N TGATGGAAGTaacAAATACTATGCAG TACCATATAACTGCCACC
D0773h1210 V50I GTGGGTGGCAattATATGGTATGATGG TCCAGCCCCTTGCCTGGA
D0773h1210 D104Y TGATAGTAGTtatTATTATGGTGATGCTTTTG CGAACTCTCGCACAGTAATAC
D0773h1210 N92Y CCAACAATATtatAATTATTGGACG CAGTAATAAGTTGCAAAATCATC
D0773h1210 Y59A AAGTAAGAAAgccTATGCAGACTCCG CCATCATACCATATAACTGCC
D0773h1210 KN93S ACAATATAATagtTATTGGACGTTCG TGGCAGTAATAAGTTGCAAAATC
2163 KS93N ACAGTATAATaatTATTGGACGTTC TGGCAGTAATAAGTTGCAAAATC
D0773h1210 HN31S CACCTTCAGTagcTATGGCATGC AATCCAGACGCTGCACAG
2163 HN31S CACCTTCAGTaacTATGGCATGC AATCCAGACGCTGCACAG
D0773h1210 Y53A AGTTATATGGgctGATGGAAGTAAGAAATACTATGCAGACTCCGTGAAGG GCCACCCACTCCAGCCCC
D0773h1210 V50A GTGGGTGGCAgctATATGGTATGATG TCCAGCCCCTTGCCTGGA
D0773h1210 V50F W52R acggTATGATGGAAGTAAGAAATACTATGCAGACTCCG ataaaTGCCACCCACTCCAGCCC
2163 V50F W52RF acggTATGATGGAAGTAATAAATACTATGCAGACTCCGTG ataaaTGCCACCCACTCCAGCCC
D0773h1450 Y59A TGGTGACACAgctTACGCGGACTC CTACTGCCACTAATACCTG
D0773h1450 S35H CTACGGCATGcatTGGGTCCGCC TTGCTAAAGCTGAATCCAG
1450 H.SGS52WYDF cgatAGTGGTGACACATATTAC taacaAATACCTGAGACCCACTC
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13.4 Expression vector maps
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13.5 List of materials
ELISA capture antibody
Goat anti-human IgG, Fcgamma Jackson, ImmunoResearch Laboratories, West Grove, PA, USA
ELISA secondary antibodies
Goat anti-human IgG, Fcgamma (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA
Goat anti-human IgM, Fc5mu (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA
Goat anti-human IgA, alpha Chain (HRP conjugated) Jackson, ImmunoResearch Laboratories, West Grove, PA, USA
ELISA standard and control antibodies
2A10 (chimeric antibody) Triller et al. 2017
Human IgG1, kappa Sigma Aldrich Chemie GmbH, Steinheim, Germany
mGO53 (non-poly-reactive antibody) Wardemann et al. 2003
FACS analysis antibodies and reagents
7-AAD Invitrogen GmbH, Karlsruhe, Germany
Mouse anti-human CD19 (BV786-conjugated, clone SJ25C1)) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD19 (PE-Cy7-conjugated, clone SJ25C1)) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD21 (PE-Cy7-conjugated, clone Bu32) BioLegend GmbH, Fell, Germany
Mouse anti-human CD27 (PE-conjugated, Nr. 555441) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human IgD (V500-conjugated, clone 1A6-2) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human IgG (APC-H7-conjugated, clone 1A6-2) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD20 (APC-H7-conjugated, clone G18-145) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD20 (BV711-conjugated, clone 2H7) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD38 (FITC-conjugated, Nr. 555459) BD Biosciences GmbH, Heidelberg, Germany
Mouse anti-human CD138 (BV421-conjugated, clone MI15) BD Biosciences GmbH, Heidelberg, Germany
Antigens
CSP Kind gift of Dr. Kim Lee Sim, Protein Potential LLC, Rockville,
MD, USA
∆-NCSP Kind gift of Dr. Silvia Boscardin, Department of Parasitology,
University of Sa˜o Paulo, Brazil
NANP5, NANP10 Alpha Diagnostic Intl. Inc., Texas, USA
NANP3 PSL GmbH, Heidelberg, Germany
Bacteria and Media
E.coli DH10B
Clonetech Inc., Palo Alto, CA, USA
LB agar Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Lysogeny broth (LB) Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Terrific broth (TB) Life Technologies GmbH, Karlsruhe, Germany
Chemicals, buffers and solutions
5x loading buffer gel electrophoresis
50x TAE buffer
ABTS self-made buffer 0.1 M citric acid, 0.2 M disodium phosphate
ABTS tablets Roche Diagnostics GmbH, Mannheim, Germany
Acetic acid (CH3COOH) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Ammonium chloride (NH4Cl2) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Ammonium sulfate ((NH4)2SO4) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Bovine serum albumin fraction V (BSA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Calcium chloride (CaCl2) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Citric acid (C6H8O7) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Cytochalasin D Sigma Aldrich Chemie GmbH, Steinheim, Germany
Dextran-rhodamine Thermo Fisher Scientific Inc., Darmstadt, Germany
Dimethyl sulfoxide (DMSO) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Disodium phosphate (Na2HPO4) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Disodium phosphate (Na2HPO4) Carl Roth GmbH & Co. KG, Karlsruhe, Germany
ELISA blocking buffer 1 (concentration ELISA) 1x PBS, 0.05% (v/v) Tween®20, 1 mM EDTA
ELISA blocking buffer 2 (antigen ELISA) 1% BSA in PBS
ELISA blocking buffer 3 (serum ELISA) 1x PBS, 0.05% (v/v) Tween®20, 4% BSA
Elution buffer pH 3 (antibody purification) 0.1 M glycine pH 3.0
Neutralization buffer pH 9.0 (antibody purification) 1M Tris
Ethanol Sigma Aldrich Chemie GmbH, Steinheim, Germany
Ethidium bromide Sigma Aldrich Chemie GmbH, Steinheim, Germany
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Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH & Co. KG, Karlsruhe, Germany
GIBCO 10x PBS (pH 7.4) Life Technologies GmbH, Karlsruhe, Germany
GIBCO 1x PBS (pH 7.4) Life Technologies GmbH, Karlsruhe, Germany
GIBCO Trypan Blue Stain 0.4% Life Technologies GmbH, Karlsruhe, Germany
Glycerol (C3H8O3) Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Glycine (C2H5NO2) Sigma Aldrich Chemie GmbH, Steinheim, Germany
H2O2 Th. Geyer GmbH & Co. KG, Renningen, Germany
Paraformaldehyde (PFA) Alfa Aesar, Thermo Fisher (Kandel) GmbH, Karlsruhe, Germany
Percoll GE Healthcare Life Sciences, Freiburg, Germany
Polyethyleneimine (PEI) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Protein G Sepharose Fast Flow GE Healthcare Life Sciences, Freiburg, Germany
SeaKem LE Agarose Cambrex Inc., Rockland, ME, USA
Sodium chloride (NaCl) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Trizma base (C4H11NO3) Sigma Aldrich Chemie GmbH, Steinheim, Germany
Tween 20 Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Cell lines and media
HC-04 BEI Resources, NIAID, NIH, Manassas, VA, USA, MRA-975, con-
tributed by J. S. Prachumsri
FreeStyle 293-F Thermo Fisher Scientific Inc., Darmstadt, Germany
Ampicillin Sigma Aldrich Chemie GmbH, Steinheim, Germany
GIBCO DMEM Life Technologies GmbH, Karlsruhe, Germany
GIBCO HEPES Life Technologies GmbH, Karlsruhe, Germany
GIBCO L-glutamine Life Technologies GmbH, Karlsruhe, Germany
GIBCO RPMI Life Technologies GmbH, Karlsruhe, Germany
GIBCO Trypsin EDTA 1x Life Technologies GmbH, Karlsruhe, Germany
FreeStyle293 Expression media Thermo Fisher Scientific Inc., Darmstadt, Germany
EX-CELL 293 Serum-Free Medium Thermo Fisher Scientific Inc., Darmstadt, Germany
Parasites
Pf NF54 Kind gift of Dr. Robert Sauerwein, Radboud University Medical
Centre, NL
Kits
AlexaFluor 647 Antibody Labeling Kit Thermo Fisher Scientific Inc., Darmstadt, Germany
NucleoBond Xtra Midi / Maxi Macherey-Nagel GmbH & Co. KG, Du¨ren, Germany
NucleoSpin 96 PCR Clean-Up Macherey-Nagel GmbH & Co. KG, Du¨ren, Germany
NucleoSpin Gel and PCR Clean-up Macherey-Nagel GmbH & Co. KG, Du¨ren, Germany
NucleoSpin Plasmid Kit Macherey-Nagel GmbH & Co. KG, Du¨ren, Germany
Enzymes and Reagents
AgeI, BsiWI, SalI, XhoI
New England Biolabs GmbH, Frankfurt am Main, Germany
Buffer 3.1 10x New England Biolabs GmbH, Frankfurt am Main, Germany
Cutsmart buffer 10x New England Biolabs GmbH, Frankfurt am Main, Germany
T4 DNA Ligase New England Biolabs GmbH, Frankfurt am Main, Germany
T4 DNA Ligase buffer 10x New England Biolabs GmbH, Frankfurt am Main, Germany
10x PCR buffer Quiagen AG, Hilden, Germany
5x First strand buffer (RT) Life Technologies GmbH, Karlsruhe, Germany
DTT Life Technologies GmbH, Karlsruhe, Germany
Hotstart Taq DNA polymerase Quiagen GmbH, Hilden, Germany
NP-40 Sigma Aldrich Chemie GmbH, Steinheim, Germany
Nuclease free water Eppendorf AG, Hamburg, Germany
RNAsin Promega Inc., Madison, WI, USA
RT buffer Life Technologies GmbH, Karlsruhe, Germany
SuperScript III Reverse Transcriptase Life Technologies GmbH, Karlsruhe, Germany
Taq DNA polymerase Self-made
1kb Plus DNA marker New England Biolabs GmbH, Frankfurt am Main, Germany
Desoxynucleotide Triphosphates (dNTPs) Life Technologies GmbH, Karlsruhe, Germany
Oligonucleotides MWG Biotech AG, Ebersberg, Germany
Random Hexamer Primers Roche Diagnostics GmbH, Mannheim, Germany
Expression vectors
1.5 ml reaction tubes Sarstedt AG, Nu¨mbrecht, Germany
2 ml reaction tubes Sarstedt AG, Nu¨mbrecht, Germany
99
13 ml tubes Sarstedt AG, Nu¨mbrecht, Germany
96-well Multiply-PCR plate Sarstedt AG, Nu¨mbrecht, Germany
96-well skirted twintech PCR plate Eppendorf AG, Hamburg, Germany
Alpha Imager 1220 Alpha Innotech Corporation Inc., San Leandro, CA, USA
Aluminum foil seal 4titude, Surrey, UK
AxioObserver Z1 fluorescence microscope ZEISS Microscopy, Oberkochen, Germany
BD Aria II BD Biosciences GmbH, Heidelberg, Germany
BD LSR II BD Biosciences GmbH, Heidelberg, Germany
BD Microlance 3 30G x 1/2” BD Biosciences GmbH, Heidelberg, Germany
BioPhotometer Eppendorf AG, Hamburg, Germany
Bio-Spin chromatography columns Bio-Rad Inc., Hercules, CA, USA
Cell culture 48-well plate TPP, Trasadingen, Switzerland
Cell culture 96-well plate TPP, Trasadingen, Switzerland
Cell culture 96-well plate (transparent bottom) TPP, Trasadingen, Switzerland
Cell culture dish (150 mm) BD Biosciences GmbH, Heidelberg, Germany
CellStar sterile serological pipettes Greiner Bio-One GmbH, Frickenhausen, Germany
Centrifuge 5180R (rotor A-4-81) Eppendorf AG, Hamburg, Germany
Centrifuge 5417R (rotor F-45-30-11) Eppendorf AG, Hamburg, Germany
CO2 Incubator CB210 Binder GmbH, Tu¨ttlingen, Germany
CryoTube Vials Thermo Fisher Scientific Inc., Darmstadt, Germany
Domed 12-cap strips (PCR tube strips) Bio-Rad Laboratories GmbH, Mu¨nchen, Germany
Electrophoresis chamber D3 (horizontal) Thermo Scientific Inc., Rochester, NY, USA
ELISA plates (96-well, flat bottom) Costar Inc., Corning, Action, MA, USA
FluoNunc Plates Costar Inc., Corning, Action, MA, USA
FrameStar 384 4titude, Surrey, UK
Heraeus B5042 (Bacteria incubator) Kendro Laboratory Products, Weaverville, NC, USA
Inoculating loops/needles, polystyrene VWR International Inc., Brigdgeport, NJ, USA
Leica DM2000 LED Leica Microsystems GmbH Wetzlar, Germany
M1000Pro plate reader Tecan, Crailsheim, Germany
Mastercycler ep Gradient S Eppendorf AG, Hamburg, Germany
Mastercycler Pro 384 Eppendorf AG, Hamburg, Germany
Multipette plus Eppendorf AG, Hamburg, Germany
Multitron Pro (Bacteria shaker) Infors HT, Bottmingen, CH
Neubauer Counting Chamber by Marienfeld Carl Roth GmbH & Co. KG, Karlsruhe, Germany
Omnican 50 Insulin Syringes, 12 mm 30 G B. Braun Medical Ltd, Sheffield, UK
Petri dishes (100 mm) Greiner Bio-One GmbH, Frickenhausen, Germany
Pipetboy acc Integra Biosciences GmbH, Fernwald, Germany
Polypropylene tubes (15 ml, 50 ml) Sarstedt AG, Nu¨mbrecht, Germany
Polystyrene round bottom tube (5 ml) with cell strainer cap BD Biosciences GmbH, Heidelberg, Germany
Slide-A-Lyzer Mini Dialysis Devices Thermo Scientific, Rockford, IL, USA
S-Monovette EDTA K Sarstedt, Nu¨mbrecht, Germany
SpectraMax 190 Microplate Reader Molecular Devices Inc., Sunnyvale, CA, USA
Stemi 2000 Stereomicroscope ZEISS Microscopy, Oberkochen, Germany
Stuart Gyro rocker SSL3 Sigma Aldrich Chemie GmbH Steinheim, Germany
T75 cm2 flask BD Biosciences GmbH, Heidelberg, Germany
Thermomixer comfort Eppendorf AG, Hamburg, Germany
Vortex genie 2 Scientific Industries Inc., Bohemia, NY, USA
Water bath with thermostat JULABO Labortechnik GmbH, Seelbach, Germany
Wax seal 4titude, Surrey, UK
Software and webservers
FlowJo v10.0 Treestar Systems Inc., Ashland, USA
GraphPad Prism 6.07 GraphPad Software Inc., La Jolla, USA
Illustrator CS5 Adobe Inc., San Jose, CA, USA
Pearl Version 12.5, open source distribution
Python Version 2.7.9, Python Software Foundation
Spyder Version 2.3.5.2
Texmaker Version 4.4.1
JabRef JabRef version 2.10
Ensemble Genome Browser release 91 [131]
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